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ABSTRACT




The restricted mean survival, first proposed by Irwin (1949), is the expected sur-
vival time within a fixed follow-up window. This measure has a meaningful interpre-
tation for both physicians and patients in a clinical setting that motivates its further
exploration.
The first paper provides a nonparametric estimate of τ -restricted mean survival
that uses additional follow-up information beyond τ , when appropriate, to improve
precision. The variance of our estimate must account for correlation between incorpo-
rated follow-up windows and we follow an approach by Woodruff (1971) that linearizes
random components of the estimate to simplify calculations. Both asymptotic closed
form calculations and simulation studies recommend selection of follow-up intervals
spaced approximately τ/2 apart.
In the second paper we develop two recurrent events testing procedures. We take
advantage of the properties of time-to-first event analyses and use events beyond the
xii
first by combining data across multiple follow-up windows in two different ways. The
first pools the data before estimating the τ -restricted mean survival and the second
uses the area under the τ -restricted mean residual life function. We consider multiple
scenarios of treatment effect in simulation studies and find our testing procedures
perform favorably, especially when events are correlated, compared to the robust
proportional rates model proposed by Lin et al. (2000) and the nonparametric Ghosh
& Lin (2000) test.
A component of the lung allocation score, used to order patients for transplant
offers, is the 1-year restricted mean survival on waitlist. In the third paper we develop
a restricted mean survival model that combines data from multiple 1-year follow-up
windows spaced six months apart to incorporate time-dependent patient risk data,
extending work by Xiang et al. (2013) to multiple follow-up intervals. Model pa-
rameters are estimated by multiply imputing censored time-to-event data using an
inverse transform method; the complete dataset is analyzed using standard methods.
The systematic removal of patients from the lung transplant waitlist based on their
daily updated LAS results in dependent censoring, which we account for using in-
verse probability of censoring weights when estimating survival functions. Simulation





The restricted mean survival time is the expected survival time within a fixed
follow-up interval. It was first proposed by Irwin (1949) since the mean survival time
is not estimable in the presence of censoring, which is almost always the case in time
to event studies. This measure has a meaningful interpretation for both physicians
and patients in a clinical setting. In addition, the restricted mean survival captures
information about the immediate future and health economists (Gyrd-Hansen & So-
gaard, 1998) have found that patients consider life-years closer to the present more
valuable than those in the future. The meaningful and relevant interpretation of the
restricted mean survival motivates its further exploration. Statistical methods for
estimation, hypothesis testing for treatment effect in a randomized clinical trial and
regression models based on the restricted mean survival have been widely studied but
research on incorporating follow-up information beyond the first follow-up window
has been limited.
The first paper provides a nonparametric estimate of τ -restricted mean survival
that uses additional follow-up information beyond τ , when appropriate, to improve
precision. The τ -restricted mean residual life function and its associated confidence
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bands are a tool to assess the stability of disease prognosis and the validity of com-
bining follow-up intervals for this purpose. The variance of our estimate, the overall
τ -restricted mean survival, must account for correlation between incorporated follow-
up windows and we follow an approach by Woodruff (1971) that linearizes random
components of the estimate to simplify calculations. Both asymptotic closed form
calculations and simulation studies recommend selection of follow-up intervals spaced
approximately τ/2 apart. In simulations, the variance we propose performs better
than the standard sandwich variance estimate. Our analysis approach is illustrated
in two settings summarizing prognosis of idiopathic pulmonary fibrosis patients and
aspirin treated diabetic retinopathy patients who had deferred photocoagulation.
In the second paper we focus on developing recurrent events testing procedures
for two independent samples. Use of a combined endpoint that includes disease pro-
gression (recurrent event) as well as mortality (terminating event) improves power for
detecting treatment effects. Standard recurrent events analyses require assumptions
about the dependence between events and time-to-first event analyses do not use the
information beyond the first event. In our approach, we take advantage of the prop-
erties of time-to-first event analyses and use events beyond the first by combining
data across multiple follow-up windows. The two testing procedures that we develop
for evaluating treatment effect combine the multiple follow-up windows in different
ways. The first uses the overall τ -restricted mean survival and the second uses the
area under the τ -restricted mean residual life function. A simulation study compares
our test to the robust proportional rates model proposed by Lin et al. (2000) and the
nonparametric Ghosh & Lin (2000) test for recurrent events subject to death. We
consider multiple scenarios of treatment effect and find our testing procedures perform
favorably, especially when events are correlated. The analysis approach is illustrated
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for a randomized trial testing the ability of azithromycin to reduce exacerbations in
patients with chronic obstructive pulmonary disease (COPD).
The motivation for the third paper comes from the lung transplant setting. The
lung allocation score (LAS) involves the difference between benefit (days of life gained
during the next year if a transplant is offered immediately) and urgency (1-year re-
stricted mean while on waitlist), and is used to order patients for organ offers. To
date, risk data at listing has been used as one of the primary drivers of model de-
velopment for the urgency model, and while time-dependent patient risk data has
been collected on the waitlist, statistical methods of incorporating this information
has been limited. We develop a restricted mean survival model that combines data
from multiple 1-year follow-up windows spaced six months apart. This is an exten-
sion of the method proposed by Xiang et al. (2013) to multiple follow-up intervals.
The model parameters are estimated by multiply imputing censored time-to-event
data using an inverse transform method to obtain complete dataset that can be an-
alyzed using standard methods. The systematic removal of patients from the lung
transplant waitlist based on their daily updated LAS results in dependent censoring
completely captured by LAS. The estimate of the survival function in the multiple
imputation procedure adjusts for the bias resulting from dependent censoring using
inverse weights. The method will also allow us to describe changes in patient urgency
over the waitlist candidate experience. The proposed method is compared to some
existing methods for fitting restricted mean survival models in simulation studies. We
found that our proposed method performs well and incorporating additional follow-
up improves efficiency. A recent release of lung waitlist data was used to implement
the proposed methodology and study the patient urgency model and the effect of
incorporating multiple follow-up windows.
CHAPTER II
NONPARAMETRIC RESTRICTED MEAN
ANALYSIS ACROSS MULTIPLE FOLLOW-UP
INTERVALS
2.1 Summary
This research provides a nonparametric estimate of τ -restricted mean survival that
uses additional follow-up information beyond τ , when appropriate, to improve preci-
sion. The τ -restricted mean residual life function and its associated confidence bands
are a tool to assess the stability of disease prognosis and the validity of combining
follow-up intervals for this purpose. The variance of our estimate must account for
correlation between incorporated follow-up windows and we follow an approach by
Woodruff (1971) that linearizes random components of the estimate to simplify calcu-
lations. Both asymptotic closed form calculations and simulation studies recommend
selection of follow-up intervals spaced approximately τ/2 apart. In simulations, the
variance we propose performs better than the standard sandwich variance estimate.
Our analysis approach is illustrated in two settings summarizing prognosis of idio-
pathic pulmonary fibrosis patients and aspirin treated diabetic retinopathy patients




Yearly progression predictions are commonly reported for clinical longitudinal
data. For example, Raghu et al. (2011) report that mild to moderate idiopathic pul-
monary fibrosis (IPF) patients tend to lose 0.2 liters in forced vital capacity lung
function per year. This is a valuable summary statistic, for physicians and patients,
that has not been sufficiently explored for censored time to event data. For instance,
it would be useful for a physician to be able to report to a patient that IPF patients
followed for 10 years were observed to live 91% of each year, on average, given they
were alive at the start of the year. This is a concise estimate for the patient about
how their disease may affect them in the short term and gives a sense of the stability
of their disease when appropriate. In cases like these where yearly progression is rea-
sonably stable, a yearly progression estimate can be made more efficient by combining
information from different follow-up periods. Pulmonary researchers and patients are
particularly primed to interpret days of life lived in a year since a lung allocation
score introduced by Egan et al. (2006) is based on expected days of life lived in the
following year without transplant.
In the Early Treatment Diabetic Retinopathy Study (ETDRS), ETDRS Research
Group (1991a,b), time to severe vision loss was the primary endpoint. In this case
an ophthalmologist might want to report the expected days of good sight per year,
given that a patient has not yet reached the severe vision loss endpoint, based on 4-5
years of observed data from this study.
The restricted mean residual life function (RMRL) is the expected days of life per
year for those surviving at the beginning of the year and may be used to view trends
in these summary statistics over time. Ghorai et al. (1982) proposed an estimator
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based on integrated conditional Kaplan-Meier estimates Ghorai & Rejto (1987) and
Na & Kim (1999) proposed a smooth-spline estimator for this quantity, among others.
Yu (2003) developed confidence bands for restricted mean residual life functions esti-
mated via Nelson-Aalen estimates, Cox model hazard estimates and inverse weighted
hazard estimates, calling them expected life prosper functions (ELPF). Stability of
these functions suggests an opportunity for producing an overall summary statistic
that is more precise.
This paper provides a nonparametric estimate of the expected number of days
lived per τ years based on A > τ years of follow-up, a single statistic describing the
cost of the disease to a patient over a stable period of time. In the IPF and diabetic
retinopathy settings described above, A is substantially greater than τ . We study sev-
eral τ -length intervals from the follow-up period to see if follow-up intervals obtained
after time zero essentially estimate the same restricted mean and if incorporating
these extra intervals provides efficiency gains. In cases where follow-up intervals give
non-stable trends for the restricted mean, the overall trend is summarized.
In Section 2.3 we review RMRL estimation, confidence band construction and a
simple RMRL smoother. Section 2.4 describes the nonparametric τ -restricted mean
survival estimator that combines information across different τ -length intervals of
follow-up. Although the data appears clustered by individual, it turns out that the
sandwich variance estimation for clustered data, available in many software pack-
ages, does not perform well when the cluster is based on many overlapping follow-up
intervals. The proposed variance described in Section 2.4 is based on a lineariza-
tion of random components of the estimator, similar to the approach recommended
by Woodruff (1971) and more recently Williams (1995). In Section 2.5 we consider
how to choose the number of follow-up intervals useful for obtaining efficiency gains.
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A simulation study that assesses the performance of the proposed estimate and its
variance against currently available competitors is presented in Section 2.6. Two ex-
amples of the proposed analysis approach, pertaining to IPF patients and diabetic
retinopathy patients, are given in Section 2.7. A discussion follows in Section 2.8.
2.3 τ-restricted mean residual life
We define notation in Section 2.3.1. Section 2.3.2 describes a nonparametric esti-
mate of RMRL, and Section 2.3.3 gives estimated confidence bands of RMRL, follow-
ing the style laid out in Yu (2003). Section 2.3.4 provides smoothed RMRL estimates
across chosen follow-up intervals as an additional visual tool for assessing whether
these follow-up intervals may be combined.
2.3.1 Notation
For each of n patients we define observed event time, Xi = min(Ti, Ci), with
failure indicator δi = I(Ti ≤ Ci), based on true failure time, Ti, and censoring time,
Ci, i = 1, . . . , n. Calendar time, t, is measured from the start of the study. We define
the residual life observed at t as Xi(t) = (Xi − t)I(Xi ≥ t) with failure indicator
variable δi(t) = δiI(Xi ≥ t).
For a τ -length interval starting at calendar time, t, the τ -restricted mean residual
lifetime is µ(t, τ) = E{min(T − t, τ)|T > t} =
∫ τ
0
Pr(T > t + u|T > t)du. Here,
u denotes an internal time scale measured from calendar time t. This definition of
RMRL, with t as a parameter, allows us to simultaneously discuss values of µ(t, τ)
measured at different calendar times t ∈ {t1, ..., tb}. We use the convention of t1 = 0
in all that follows.
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Counting process notation includes the two timescales described, t (calendar) and
u (internal time measured from t). For individual i at calender time t, the event
counting process applied to internal timescale u is Ni(t, u) = I{Xi(t) ≤ u, δi(t) = 1}
with at-risk process Yi(t, u) = I{Xi(t) ≥ u}. At t, the total number of events
occurring no later than u is N(t, u) =
∑n
i=1Ni(t, u) and the number at risk at u is
Y (t, u) =
∑n
i=1 Yi(t, u). We require notation combining counting process quantities
across calendar times, {t1, ..., tb}. For individual i and internal time u, Ni(u) =∑b
k=1Ni(tk, u) and Yi(u) =
∑b
k=1 Yi(tk, u). Combining information across follow-
up intervals and patients gives us N(u) =
∑b
k=1N(tk, u), total number of events
occurring no later than u, and Y (u) =
∑b
k=1 Y (tk, u), total number at risk at u.
Many of the {Xi(tk), δi(tk)} pairs reflect follow-up times censored at time 0 due to
attrition prior to time tk.
2.3.2 Estimation of τ-restricted mean residual life
The τ -restricted mean residual lifetime function, µ(t, τ), tracks subsequent ex-
pected lifetime during an interval of length τ given the patient has survived up to
time t. Henceforth we call µ(t, τ) the RMRL function, submerging τ for brevity. Us-
ing notation from the previous section, a consistent nonparametric estimator of the
RMRL function is µ̂(t, τ) =
∫ τ
0










We slightly modify work from Yu (2003) for RMRL confidence band calculations
applied to times {t1, . . . , tb}. As opposed to 95% pointwise confidence intervals, de-
signed to cover each separate µ(t, τ) value 95% of the time, confidence bands are
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designed to cover the entire set of values {µ(t1, τ), . . . , µ(tb, τ)} 95% of the time.
Plotting the RMRL function with its corresponding bands is useful in suggesting
whether follow-up windows may be combined for estimation or not.
Technical development of confidence bands for {µ(t1, τ), . . . , µ(tb, τ)} is based on
the Gaussian process B(t, τ) = n1/2{µ̂(t, τ) − µ(t, τ)} and the covariance of this
process at times tj1 and tj2 , j1 = 1, . . . , b, j2 = 1, . . . , b. The estimated covariance
matrix
∑̂














dNi(tj1 , u)dNi(tj2 , v)
Y (tj1 , u)Y (tj2 , v)
ds ds′
Following Lin et al. (1994), the asymptotic distribution of {B(t1, τ), . . . , B(tb, τ)}
is approximated by generating a large number of mean zero multivariate Normal
samples using the observed covariance structure,
∑̂
b×b. Using these samples, we
calculate qα satisfying Pr{maxt∈{t1,...,tb} |B̂(t, τ)| > qα} = α. Level 100(1 − α)%
confidence band values surrounding µ(t, τ) become
[
µ̂(t, τ) − n−1/2 × qα, µ̂(t, τ) +
n−1/2 × qα
]
, calculated at times t = {t1, . . . , tb}. In practice, these confidence bands
perform well provided that there are at least 25 event times following tb.
2.3.4 Smoothed RMRL estimated at times t = {t1, . . . , tb}
Smoothed RMRL values can be useful in visualizing trend from noise across follow-
up intervals. For each follow-up interval, {tk, tk +τ}, k = 1, . . . , b, adjoining follow-up
windows contribute information towards estimation of the smoothed RMRL estimate
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at tk, µ̂












j=k Y (tj ,u)
}









j=k−1 Y (tj ,u)
}









j=k−1 Y (tj ,u)
}
ds k= b
Each smoothed RMRL value at time tk is a special case of the overall τ -restricted
mean survival function developed in the next section. These smoothed RMRL values
are superimposed on RMRL plots.
2.4 Overall τ-restricted mean survival
When the RMRL (discussed in Section 2.3.2) and its corresponding confidence
bands (discussed in Section 2.3.3) do not indicate a strong trend, we develop a more
efficient estimate of the expected number of days lived in the next τ years by pooling
appropriate follow-up periods beginning at times t ∈ {t1, ..., tb}. In Section 2.4.1 we
define our proposed estimate of the overall τ -restricted mean survival. The variance
of this estimate is developed in Section 2.4.2.
2.4.1 Estimation













Let λ(tk, u) = lim∆u→0[Pr{u ≤ Xi(tk) < u + ∆u, δi(tk) = 1|Xi(tk) ≥ u}/∆u]
and let λW (u) =
∑b
k=1 λ(tk, u)Pr{Xi(tk) ≥ u}/
∑b
l=1 Pr{Xi(tl) ≥ u}. In Appendix
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which is the mean of the mixture distribution created from combining follow-up times
across the different intervals. If the overall dataset reflects a single distribution, that
is, λ(tk1 , u) = λ(tk2 , u) for 0 ≤ u ≤ τ and k1, k2 ∈ {1, ..., b}, then µ∗(τ) reduces to
µ(t1, τ), the usual restricted mean that is typically estimated using a single follow-
up period. Variance calculations in the following section acknowledge the potential
mixture of hazards that might occur when combining follow-up times across intervals.
2.4.2 Variance of proposed estimate
The proposed variance estimate is calculated via linearizing components of
√
nµ̂∗(τ)
via Taylor series approximations. This approach to obtaining variances is an attrac-
tive alternative to working through stochastic integrals of martingales for correlated
counting process, where appropriate filtrations can be challenging to define. Suppose
that in the dataset of combined follow-up times we observe M events at internal times
{0 < T1 < . . . < TM < τ} where events from the same individual during different
follow-up windows are correlated; for convenience, we define T0 = 0 and TM+1 = τ .
Let Fj{dN(Tj), Y (Tj)} = dN(Tj)/Y (Tj). In the following we temporarily submerge
arguments of Fj. We define Gm(F0, F1, . . . , Fm) = exp(−
∑m
j=0 Fj). After rewriting
√









(Tm+1 −Tm)Gm(F0, F1, . . . , Fm)
}
.
The non-linear terms G0, G1, . . . , GM may be made more tractable for variance
calculations via linearization based on a Taylor series expansion of Gm(F0, F1, . . . , Fm)
about λW (Tj)dTj, j = 0, . . . ,m. The first order partial derivatives ofGm(F0, F1, . . . , Fm)
12






















































































(Tm+1 −Tm) [ higher order terms]
)
. (2.2e)
Terms (2.2a) and (2.2c) are nonrandom and therefore do not contribute to the
variance. The fourth term (2.2d) converges to zero in probability, details given in
Appendix A.2. Similarly all higher order terms of the Taylor series linearization (2.2e)














, the variance of a linear sum of non-linear com-
ponents F0, F1, . . . , FM .
Each of the non-linear Fj terms may be made more tractable for variance calcula-
tions via further linearization based on a Taylor series expansion of Fj{dN(Tj), Y (Tj)}
about the expected values of dN(Tj) and Y (Tj). The expected value of dN(Tj) is
n
∑b
k=1 λ(tk,Tj)Pr{Xi(tk) ≥ Tj}dTj and the expected value of Y (Tj) is n
∑b
k=1 Pr{
Xi(tk) ≥ Tj}. The ratio of the expectations, E{dN(Tj)}/E{Y (Tj)}, simplifies to
λW (Tj). The first-order partial derivative of Fj with respect to dN(Tj) is 1/Y (Tj)























































{ higher order terms}
]
. (2.3e)
Term (2.3a) is a constant and therefore does not contribute to the variance. Terms
(2.3b) and (2.3c) simplify to
∑m
j=0 [dN(Tj)− Y (Tj)E{dN(Tj)}/E{Y (Tj)}] /E{Y (Tj)}.
The fourth term (2.3d) converges in probability to zero, details given in Appendix
A.2. Similarly, all higher order terms of the Taylor series linearization (2.3e) converge




k=1 dNi(tk,Tj) and Y (Tj) =∑n
i=1
∑b
k=1 Yi(tk,Tj). The expected value of dN(Tj) is n
∑b
k=1 λ(tk,Tj)Pr{Xi(tk) ≥
Tj}dTj and the expected value of Y (Tj) is n
∑b
k=1 Pr{Xi(tk) ≥ Tj}. The variance





















l=1 Pr{Xi(tl) ≥ Tj}
.
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Whereas event times across overlapping follow-up periods are generally not i.i.d.,
the Zi{µ̂∗(τ)} terms are i.i.d., making empirical variance estimates based on Zi{µ̂∗(τ)}







/(n− 1) where Z̄{µ̂∗(τ)} =
∑n
i=1 Zi{µ̂∗(τ)}/n. The














dNi(tk,Tj)− dN(Tj)Y (Tj) Yi(tk,Tj)
Y (Tj)/n
In understanding design issues discussed in Section 2.5, it is convenient to have




















dNi(tk, u)− λW (u)Yi(tk, u)du∑b
l=1 Pr{Xi(tl) ≥ u}
]
ds






























l′=1 Pr{Xi(tl′) ≥ u}
] [∑b
l′=1 Pr{Xi(tl′) ≥ v}
]
[
λ(tk, u)Pr{Xi(tk) ≥ u}I(v = u+ tk − tl)du
−λW (u)λ(tl, v)Pr{Xi(tl) ≥ v}{I(u ≤ v + tl − tk) + I(u = 0)I(v < tk − tl)}du dv
−λW (v)λ(tk, u)Pr{Xi(tk) ≥ u}{I(v ≤ u+ tk − tl) + I(v = 0)I(u < tl − tk)}du dv
+λW (u)λW (v)Pr{Xi(tk) ≥ u,Xi(tl) ≥ v}du dv





Number and spacing of follow-up windows should be chosen to increase precision
of µ̂∗(τ). For this purpose, we examine the estimator’s closed form variance σ2 in
the special case where the failure time, Ti, follows an exponential distribution with
hazard λ. The censoring time, Ci, is independently sampled from a Uniform[A −
A∗, A] distribution, where A is the length of the study with accrual time A∗. In this
case, λ(tk, u) = λ
W (u) = λ. Standard probability calculations for u, v ∈ (0, τ ] give
Pr{Xi(tk) ≥ u} = exp{−λ(u+ tk)}{A−max(A− A∗, u+ tk)}/A∗ and Pr{Xi(tk) ≥
u,Xi(tl) ≥ v} = exp {−λmax (u+ tk, v + tl)} {A −max(A − A∗, u + tk, v + tl)}/A∗.
Details of these calculations are given in Appendix A.4.
We consider τ = 1 year. The parameter λ was chosen to give a constant 1-year
RMRL of 11 months, A∗ = 1 year, A = 3 years and n = 100. Figure 2.1 shows
the behavior of σ2/n, the finite sample size variance, for three one-year follow-up
windows with t1 = 0, t3 = 12 months and t2 varying between these values. The
one-year windows starting at t1 and t3 do not overlap, so the choice of t2 examines if
there is an advantage to adding a 3rd follow-up window that overlaps the other two.
The plot suggests that an additional 1-year window starting in the middle of t1 = 0
and t3 = 12 months, i.e. at t2 = 6 months, reduces the variance the most.
Next consider (1) whether additional equally spaced follow-up windows further
reduce σ2/n and (2) the extent to which incorporating an additional year’s worth of
follow-up information, and corresponding 1-year windows, into construction of µ̂∗(τ)
reduces its variability. The first entry of Table 2.1 corresponds to the variance ob-
tained if estimating the standard 1-year restricted mean that doesn’t use information
from additional follow-up intervals. For a given tb of 12 or 24 months, increasing
16
Figure 2.1: Closed form asymptotic variance of µ̂∗(τ) for 3 year study with τ=1 year,
t1 = 0, t3 = 12 months and varying t2. Dashed line corresponds to
variance of estimator constructed using two follow-up windows t1 = 0
and t3 = 12.
the number of follow-up windows improves the precision of the estimator. However,
there are diminishing returns from introducing starting times more frequently than
at 6-month intervals.
Table 2.1: Study of follow-up window choices based on calculated variance and
Asymptotic Relative Efficiency (ARE) for the special case discussed in
Section 4.
Number of {t1, . . . , tb} σ2/n ARE
Windows
tb = 0 1 0 0.071 1.00
tb = 12
2 0, 12 0.039 1.82
3 0, 6, 12 0.035 2.03
5 0, 3, 6, 9, 12 0.035 2.03
tb = 24
3 0, 12, 24 0.030 2.37
5 0, 6, 12, 18, 24 0.026 2.73
9 0, 3, 6, 9, 12, 15, 18, 21, 24 0.025 2.84
It seems clear from exploration of this special case that spacing of t1, . . . , tb should
be at 6-month intervals when estimating an overall 1 year restricted mean, with
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tb = 24. In general, the recommended number of intervals is based on available follow-
up time and we propose using intervals starting from tk = (k − 1) τ2 for k = 1, . . . , b,
with tb less than A− τ .
2.6 Simulation Study
Simulation experiments were conducted to assess finite sample size performance
of µ̂∗(τ). We consider whether augmenting the first observation window improved
the estimator and the effect of the number of intervals on the performance of the
estimator. The performance of our proposed variance estimate is compared to a
variance estimate that assumes independence and the sandwich variance (formulae to
calculate these are given in Appendix A.5).
The simulation experiment design assumes we wish to estimate 12-month re-
stricted mean survival in a 36-month study. We assume that 30% of the sample
(n = 100) were recruited at the start of the study and were observed for the full 36
months. The remaining 70% were uniformly accrued over the first 12 months. Ti
was simulated from a piecewise Weibull distribution with parameters chosen so that
the 12-month restricted mean survival was 11 months at the recommended follow-up
times tk ∈ {0, 6, 12, 18, 24}, k = 1, . . . , 5. The hazard function of the piecewise Weibull
distribution is given by λ(x) = αiλix
αi−1, where the parameters are constant within
a 6 month interval. The parameters are defined as α = (1.1, 0.9, 1.1, 0.9, 1.1, 0.9) and
λ = (1.25, 2.01, 1.05, 2.00, 1.26, 0.10)× 10−2.
Simulation results in Table 2.2 show that augmenting the data with additional
follow-up time improves the precision of the estimator, with ARE ranging from 1.87
to 2.70. The bias is minimal in all cases. As expected based on Section 2.5, the
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Table 2.2: Study of follow-up windows and performance of variance estimators in 500
Monte Carlo simulations (n = 100) from a piecewise Weibull distribution
{t1, ..., tb} Emp Emp Independent Sandwich Proposed
Mean Var Variance Variance Variance
Emp Cov Emp Cov Emp Cov
Mean 95% CI Mean 95% CI Mean 95% CI
0 10.986 0.073 0.070 0.938 0.069 0.938 0.070 0.938
0, 12 10.993 0.039 0.039 0.938 0.039 0.934 0.039 0.940
0, 12, 24 10.975 0.030 0.031 0.954 0.031 0.952 0.031 0.952
0, 6, 12, 18, 24 10.980 0.027 0.018 0.878 0.021 0.902 0.028 0.948
The following abbreviations are used: Empirical Mean(Emp Mean);
Empirical Variance (Emp Var);
Coverage of 95% confidence interval (Cov 95% CI)
case with {t1, . . . , t5} = {0, 6, 12, 18, 24} outperforms other scenarios for, b = 1, 2, 3.
All three variance methods perform well when {t1, . . . , tb} produced disjoint intervals
(rows 1−3 of Table 2.2). With overlapping intervals, the proposed variance gives the
best coverage; independent and sandwich variances both underestimate the simulation
empirical variance.
2.7 Examples
In a study by Schmidt et al. (2012), which aimed to provide better prognostic
information to idiopathic pulmonary fibrosis (IPF) patients, 734 patients were identi-
fied through interstitial lung disease databases from three referral centers, the Royal
Brompton and Harefield National Health Service Foundation Trust, National Jew-
ish Health and the University of Michigan Health System, from 1981 through 2008.
There is currently no effective treatment for IPF, with patients experiencing a steady
average decline in lung function per year. A natural question is whether the expected
number of days of life in the next year is also stable.
For each patient, calendar time begins at first pulmonary function test at their
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referral center within the study period. As recommended, one-year intervals with start
times every six months are used. The final interval at 9.5 years, chosen to ensure at
least 25 risk set deaths remaining, used follow-up through year 10.5. The smoothed
RMRL in Figure 2.2(a) fluctuates between 329 and 343 days with more stability in
the first 6 years, where there is more available data. The confidence bands suggest
that it is still reasonable to report an overall point estimate that the average number
of days of life lived in the next year is 333.6 (95% CI: 330.7-336.4). During the first
decade of their disease, IPF patients are expected to live 91% of each year given they
were alive at the start of the year.
The Early Treatment Diabetic Retinopathy Study (ETDRS) (ETDRS Research
Group, 1991a,b) enrolled patients with severe diabetic retinopathy in both eyes who
were taking Aspirin daily. In addition one eye of each patient was randomly assigned
to early photocoagulation and the other to deferral of photocoagulation until a later
time when high-risk proliferative retinopathy was detected. We focus on the 583
patients who were randomized to the deferred photocoagulation treatment group.
The major endpoint of interest was time to severe vision loss, defined as visual acuity
less than 5/200 at two consecutive visits.
One-year intervals with start times every six months are used. The final interval
at 3.5 years, chosen to ensure at least 25 risk set deaths remaining, used follow-up
through year 4.5. The smoothed RMRL in Figure 2.2(b) suggests a slightly declining
trend, reflecting somewhat quicker eyesight deterioration over time despite initiation
of therapy once patients became especially high risk. Given the narrow width of
the confidence bands (< 10 days), one may argue that it is reasonable to report an
overall point estimate of average days of sight per year, 362.2 days (95% CI: 361.3-
363.1), which falls within the reported confidence bands through the 3.5 year period
20
considered. In this case, it may also be instructive to include the graphic so that
future potential trend may be monitored.











































































Figure 2.2: One-year restricted mean residual life function (solid) evaluated every
six months. Associated CB are given (dashed) as well as the smoothed
restricted mean residual life function (long dash).
2.8 Discussion
We have developed a summary statistic of the expected number of days lived
in the next τ years that uses additional follow-up information when we observe a
stable disease progression. The RMRL plot at each time t1, . . . tb tracks the expected
lifetime in the next τ years given the patient has already lived up to time tk, k =
1, . . . , b. The RMRL plots and associated confidence bands provide a summary of the
trend in disease progression. They are a useful diagnostic tool to assist in deciding
whether disease progression is stable, i.e. the RMRL is the same at each t1, . . . tb, or
not. In cases where we observe stable disease progression the additional incorporated
follow-up windows give a more precise estimate of the τ -restricted mean survival. An
obvious example of stable disease progression is exponential failure times. However,
more generally, the RMRL is stable across b windows of follow-up when λ(tk1 , u) =
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λ(tk2 , u) for 0 ≤ u ≤ τ and k1, k2 ∈ {1, ..., b}. We showed consistency of our overall
τ -restricted mean survival in this case. We also suspect that in cases where the
integrated survival curves within the follow-up windows are equivalent, our estimate
is consistent. A rigorous proof backing up this intuition has eluded us, although
special cases of distributions with this property have given µ∗(τ) = µ(t1, τ) and
simulations also appear to perform well in these settings.
The empirical variance estimate we describe is straightforward to program and per-
formed quite well in finite sample simulations, improving upon sandwich estimation
variance results that seem to break down when follow-up intervals overlap. Although
our calculations for determining the optimal number of follow-up windows was based
on a 1-year follow-up period, these results generalize to any linear transformation of
this time-scale and so our results extend to more general cases encountered in clinical
trials or observational studies.
Our method pools the data and estimates the τ -restricted mean survival in a
combined dataset. We initially considered an alternative method of using additional
follow-up information that estimates the τ -restricted mean survival as a weighted
average of RMRL estimates across the follow-up intervals. This approach was ex-
plored in simulations, for the same Weibull setting we used in Section 2.6, but was
found to be less efficient than our recommended method and was not pursued further.
Something similar was documented in Murray & Tsiatis (1996, 2001), where weighted
averages of integrated survival curves across strata could actually result in reduced
efficiency when strata were not prognostically different from one another. That would
be the case in our setting where stability of progression across follow-up windows is
required before combining data into an overall dataset.
CHAPTER III
NONPARAMETRIC TESTS OF TREATMENT
EFFECT FOR A RECURRENT EVENT
PROCESS THAT TERMINATES
3.1 Summary
Recurrent and terminal events are common outcomes for studying treatment ef-
fects in clinical studies. Existing approaches follow either a time-to-first event analysis
approach or a recurrent event modeling approach. Recurrent event analyses are often
restricted by independence assumptions on gap-times between events. Although time-
to-first event analyses are not subject to this restriction, they discard information that
occurs beyond the initial event and are much less powerful for detecting treatment
differences. We develop two new approaches for determining treatment effects, mo-
tivated by less restrictive assumptions of time-to-first event analyses, that combine
information from multiple follow-up intervals. The first testing procedure pools (cor-
related) short term τ -restricted outcomes from pre-specified intervals starting at times
tk, k = 1, . . . , b, and compares estimated τ -restricted mean survival across treatment
groups from this combined dataset. The second procedure calculates conditional τ -
restricted means from those at risk at times tk, k = 1, . . . , b and compares the area
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under a function of these by treatment. Variances calculations, taking into account
correlation of short-term outcomes within individuals, linearize random components
of the test statistics following Woodruff (1971) and more recently Williams (1995).
Simulations compare the finite sample performance of our tests to the robust propor-
tional rates model proposed by Lin et al. (2000) and the Ghosh & Lin (2000) test for
recurrent events subject to death. In treatment effect patterns following proportional
incidence rates, delayed treatment effect and short duration treatment effect, the pro-
posed methods perform favorably when compared to existing methods. These new
analysis approaches also produce correct type I error rates when gap-times between
events are correlated. The analysis approach is illustrated in data from a randomized
trial of azithromycin in patients with chronic obstructive pulmonary disease (COPD).
3.2 Introduction
Clinical studies, where the outcome of interest is time-to-event, often use a com-
bined endpoint that includes disease progression as well as mortality to improve the
power of the study. For example, in idiopathic pulmonary fibrosis (IPF) studies the
combined endpoint often used is time to death, lung transplant, acute exacerbation,
10% decline in forced vital capacity (liters) or 15% decline in diffusing capacity of the
lung for carbon monoxide (ml/min/mmHg), whichever occurs first. This endpoint is
a combination of recurrent and terminating events, where multiple recurrent events
are observed in some patients. An analysis to test treatment effect based on time-
to-first event will ignore the information contained in later recurrent events and in
terminating events observed after a recurrent event. Alternatively, typical recurrent
event analyses on gap-times require independent gap-times to avoid bias from de-
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pendent censoring, which is sometimes a deterrent from use of these analyses in the
clinical trial setting. The aim of our testing procedure is to extract information from
both recurrent and terminal events regarding treatment effect while approaching the
data from a perspective closer to time-to-first event analysis that avoids independence
assumptions and dependent censoring issues.
One advantage of time-to-first event analyses is the immediate applicability to
patients about what will happen to them next. For instance, the combined endpoint
for IPF studies mentioned above is relevant to the subsequent year of life for the
patient. Health economists have noted that patients value life-years closer to the
present more than those in the future, Gyrd-Hansen & Sogaard (1998). This motivates
a testing procedure that captures short term outcomes and how they evolve over time.
One potential short term summary statistic is τ -restricted mean survival; for the
IPF study a 1-year restricted mean would be suitable. However, a standard 1-year
restricted mean survival estimate ignores data collected after year one that could
contain information on treatment effect. If additional 1-year follow-up windows are
available beyond the first year, then they would add information on short term out-
comes at different stages of the trial.
We embrace the philosophy that understanding short-term windows of treatment
effect can provide an alternative and potentially superior understanding of treatment
effect throughout the trial. We propose combining times-to-first-event across multiple
follow-up windows of length τ beginning at evenly spaced times t ∈ {t1, . . . , tb}. The
choice of the spacing between {t1, . . . , tb} is based on reducing the variance of the
restricted mean. Each starting point tk of a follow-up interval is chosen as part
of a study design, not influenced by observed data, and so avoids complications of
dependent censoring that a gap-time analysis would pose for this data structure.
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We develop two methods of combining information from follow-up windows in two-
sample testing procedures. The first statistic pools data across each of the τ -length
follow-up windows and estimates the τ -restricted mean survival in this combined
dataset. The variance of this estimate is based on a linearization of random compo-
nents of the estimator, similar to the approach recommended by Woodruff (1971) and
more recently Williams (1995). An alternative statistic combines information across
follow-up intervals by first creating a function of conditional τ -restricted means among
those at risk at tk, k = 1, . . . , b and then calculating the area under this function as a
summary statistic for comparison between treatment groups.
There are a number of advantages of our analysis approach for this type of clinical
trial. First, we include both recurrent and terminating events by defining time-to-
event as a combined endpoint, so treatment differences should emerge with respect to
either type of process. Second, we incorporate data collected beyond τ and account for
resulting correlation between multiple follow-up windows for each patient. Variance
calculations do not require any assumptions about the correlation structure between
events observed for each patient. Third, by fixing the follow-up window start times
we do not create the problem of dependent censoring commonly encountered when
modeling gap-times between recurrent events.
Section 3.3 describes the notation used in the testing procedure. In Section 3.4
we propose two test statistics for comparing treatment effect in a randomized trial.
A simulation study is used to compare the proposed two-sample tests to the robust
proportional rates model proposed by Lin et al. (2000) and the Ghosh & Lin (2000)
test for recurrent events subject to death in finite sample size settings in Section 3.5.
The analysis approach is illustrated in Section 3.6 using data from a randomized trial
of azithromycin in patients with chronic obstructive pulmonary disease (COPD). A
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discussion follows in Section 3.7.
3.3 Notation
Consider the following data structure: Di is the death time and Ci is the indepen-
dent censoring time for patient i = 1, . . . , n. For patient i we define Ti1 < Ti2 < . . . <
TiJi as recurrent event times terminating with death, i.e. TiJi = Di. Although we
assume Ci is independent of Tk, k = 1, ..., Ji, the recurrent event times and the death
time may be correlated. The process may not be fully observed due to censoring and
we define the observed data for each patient to be Xij = min(Tij, Ci) with failure
indicator variable δij = I(Tij ≤ Ci) for j = 1, 2, . . . , J̃i, where J̃i ≤ Ji.
Since our analysis approach is to combine time-to-first event outcomes across
multiple pre-specified intervals beginning at times t ∈ {t1, . . . , tb}, with t1 = 0 in all
that follows, we define for patients at risk at time t
ηi(t) = min{j = 1, . . . , J̃i : Xij ≥ t}
Xi(t) = Xiηi(t) − t
δi(t) = δiηi(t)
where Xi(t) is the observed time to the next event from t, ηi(t) is the corresponding
index of the observed event time and δi(t) is the associated failure indicator variable.
Otherwise, if a patient is not at risk at time t, we use the convention that Xi(t) =
δi(t) = 0.
For a follow-up interval starting at t, the time to the next event is censored at
time Ci − t, which is independent of Xi(t). This would not be the case if we were
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considering gap times between recurrent events, except in the special case where gap
times are independent of one another. Gap times are traditionally defined as Si1 = Ti1
and Sij = Tij − Ti(j−1) for j = 2, 3, . . . , Ji. When gap times Sij are correlated, their
corresponding censoring times Ci − Ti(j−1) become dependent on earlier gap times as
well. Focusing on times to the next event from prespecified times t1, . . . , tb avoids
dependent censoring issues faced by gap time analysis approaches, while still taking
advantage of additional recurrent event information.
For defining counting process notation, we have two time scales indexed by t and
u. The t notation defines the beginning of each pre-specified follow-up interval as
measured from the patient’s randomization time. The u notation follows continuous
time within any particular follow-up window, indexing the statistical processes from
0 to τ . We define the event counting process for each time to first event analysis
starting at t as Ni(t, u) = I{Xi(t) ≤ u, δi(t) = 1} and the at-risk process as Yi(t, u) =
I{Xi(t) ≥ u}. For the interval starting at t, N(t, u) =
∑n
i=1Ni(t, u) counts the
number of first events from the start of the interval to u and Y (t, u) =
∑n
i=1 Yi(t, u)
gives the number at-risk at time u for a first event in the interval. The hazard
rate within each follow-up interval is defined as λ(t, u) = lim∆u→0[Pr{u ≤ Xi(t) <









k=1 Yi(tk, u) as the counting and at-risk processes for data that is
pooled across follow-up windows. In the remainder of the manuscript, a subscript g
is inserted as the first index to indicate treatment group; otherwise notation defined
in this section is unchanged.
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3.4 Constructing the Two-Sample Tests
3.4.1 Overall τ-restricted mean test
The first proposed summary statistic that we use to compare treatment groups
pools data from each of the follow-up windows when estimating a τ -restricted mean












ds where g = 1, 2.
Let λWg (u) be defined as
∑b
k=1 λg(tk, u)Pr{Xgi(tk) ≥ u}/
∑b











ds is the mean of the mixture distribution created
from combining times-to-first event across the different follow-up intervals. In Ap-
pendix A of the Supplementary Materials, we show that
√
ng{µ̂∗g(τ)−µ∗g(τ)} converges





























The variance calculations avoid assumptions about the correlation structure be-
tween follow-up intervals within a subject, while taking into account that some of
these intervals overlap and some do not. This is a somewhat weaker assumption
than what is typically used when calculating robust (sandwich) covariance structures.
Sandwich covariance between follow-up intervals [0,12) and [6,18) would assume the
same correlation structure for each individual contributing to the analysis, when in
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reality, some times-to-first event in these two intervals contain overlapping follow-up
segments (e.g., long event times) and some do not (e.g., short event times). In ex-
ploratory work, we found that the robust covariance estimated some mixture of these,
which affected inference in finite sample sizes.
Let πg be proportion of individuals in group g, g = 1, 2, which can be consis-
tently estimated with π̂g = ng/(n1 + n2). A nonparametric test statistic comparing











2(τ), T∗ has a mean zero normal limiting









∗2, as shown in more detail in Appendix B of the Supplementary Materials.
3.4.2 Area under the τ-restricted mean residual lifetime function test
An alternative testing procedure is based on a function of conditional τ -restricted
means, hereafter called the τ -restricted mean residual lifetime function (RMRL) and
denoted by µg(t, τ). This is the expected time to the next event during an interval
of length τ given the patient has survived up to time t in each group g = 1, 2. A











. The area under µg(t, τ) from t1 to tb






In Appendix C of the Supplementary Materials we show that
√
ng{µ̂g(·, τ)−µg(·, τ)}
converges in distribution to a normal random variable with finite variance that is
estimated by σ̂2R,g =
∑ng
i=1 [zi{µ̂g(·, τ)} − z̄{µ̂g(·, τ)}]
2 / (ng − 1) where z̄{µ̂g(·, τ)} =∑ng


















A nonparametric test statistic comparing the integrated τ -RMRL in two indepen-





{µ̂1(·, τ)− µ̂2(·, τ)} .
Under the null hypothesis of no difference in the area under the τ -RMRL between
the two treatment groups, TR converges in distribution to a mean zero normal dis-









see Appendix D of the Supplementary Materials for more details.
Although not required for technical results to hold, we have found it convenient
to estimate µ̂g(·, τ) using a reduced number of timepoints t1, . . . , tb and trapezoidal
rule integration for faster computation. In this case µ̂g(·, τ) becomes
∑b−1
k=1(tk+1 −
tk) {µ̂(tk+1, τ) + µ̂(tk, τ)} /2 and zi{µ̂g(·, τ)} =
∑b−1
k=1(tk+1 − tk) [zik{µ̂(tk+1, τ)}+


















The power of T∗ and TR, are affected by the choice of τ and, for T∗, the number
and spacing of the follow-up intervals. Recall that in each follow-up interval of length
τ , we only use information up to the first event time. Hence as τ gets larger, the
potential loss of information increases as opposed to a gap-time oriented analysis. For
this reason, we recommend a follow-up window length that is clinically meaningful
and long enough for a treatment difference to emerge, but not excessively long. For
example, in our pulmonary setting many study designs are centered on one-year
differences, suggesting τ = 1 year as a clinically meaningful window length. Since
exacerbation rates average 1-2 per year in this setting, the choice of one year is also
reasonable enough to detect treatment differences without ignoring much follow-up
information in each window.
We advocate choosing {t1, . . . , tb} so that we have the most precise estimate of the
statistic µ∗(τ). In Appendix E of the Supplementary Materials, we summarize closed
form variance calculations and simulations for the special case when a single event is
observed for each patient. In short, we observe diminishing returns in precision gains
from introducing starting times tk, more frequently than τ/2 units apart, so that
follow-up intervals starting from tk = (k − 1)τ/2 for k = 1, . . . , b are recommended,
where b is chosen so that the final follow-up interval starting at tb does not exceed
the study period.
3.5 Simulations
Simulations based on 500 iterations, with n1 = n2 = 100, study finite sample
properties of the proposed two-sample tests. The proposed 36-month study has a
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12-month patient accrual period, where 30% of the sample is recruited at the start of
the study and observed the full 36 months; the remaining 70% are uniformly accrued
over the first 12 months, i.e., a uniform(24,36) administrative censoring mechanism.
To generate correlated recurrent and terminating events we first simulate mean
zero multivariate normal random variables Uij, j = 1, 2, . . . , Ji and Vi with Var(Uij) =
Var(Vi) = 1 for j = 1, 2, . . . , Ji, corr(Uij, Uij′) = ρ1 for j 6= j′ and corr(Uij, Vi) = ρ2.
The parameter ρ1 controls the correlation between gap times and the parameter ρ2
controls the correlation between the gap times and the time to death. Using the
probability integral transform method we then convert these multivariate normal
random variables Uij, j = 1, 2, . . . , Ji and Vi to correlated uniformly distributed ran-
dom variables U ′ij, j = 1, 2, . . . , Ji and V
′
i . Finally, the inverse probability integral
transform method is used to obtain correlated exponentially distributed gap times
Sij, j = 1, 2, . . . , Ji and time to death Di. In the simulations that follow we assume
either independence (ρ1 = ρ2 = 0) or dependence (ρ1 = 0.5, ρ2 = 0.3) of events
observed within individual.
Group 1’s gap time incidence rate is λS1 = 1/12 with death hazard λD1 = 1/36.
We consider three scenarios for treatment effect in group 2: an immediate treatment
effect, a treatment effect that is delayed by 6 months and a treatment effect that
vanishes after 12 months. In each case for group 2 when the treatment effect is
active, the gap time incidence rates change to λS2 = λS1 ∗ α and the death hazard
changes to λD2 = λD1 ∗ α where α takes on values {1, 0.9, 0.8, 0.7, 0.6}.
The performance of the proposed two-sample tests, T∗ and TR, are compared to
the performance of the robust proportional rates model of Lin et al. (2000) (TPM)
applied to the combined event of recurrence or death, the combined statistic of Ghosh
& Lin (2000) with equal weights for recurrent and terminal endpoints (TGL) and the
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standard time-to-first event analysis based on the logrank test (TLR).
Type I errors of all statistics are presented on first line of Table 3.1 for the case
where treatment effect is immediate and carries through the duration of the trial. For
each correlation structure, tests maintain type I error rates around the nominal level
of 0.05 (within a 95% CI of 0.031-0.069). When the recurrent and terminating events
are independent (ρ1 = ρ2 = 0), the robust proportional rates model is observed to be
the most powerful test, with the power of our tests close to that of Ghosh and Lin
and larger than the standard logrank time-to-first-event analysis.
When events are correlated (ρ1 = 0.5, ρ2 = 0.3) , our proposed tests are observed
to be more powerful than the alternatives. The power of TPM and TLR are comparable
and slightly larger than that seen with TGL. Hence, our proposed tests are seen to
best handle the correlated event data, while taking into account termination by death
in a natural way.
Table 3.1: Power of two-sample hypothesis tests in 500 Monte Carlo simulations for
scenario one where we assume proportional incidence rates in the two treat-
ment groups and that treatment is effective immediately.
ρ1 = 0, ρ2 = 0 ρ1 = 0.5, ρ2 = 0.3
α T∗ TR TPM TGL TLR T∗ TR TPM TGL TLR
1.0 0.042 0.033 0.044 0.046 0.048 0.036 0.054 0.050 0.044 0.044
0.9 0.160 0.156 0.190 0.158 0.112 0.116 0.107 0.104 0.092 0.108
0.8 0.520 0.476 0.648 0.560 0.306 0.356 0.340 0.316 0.224 0.302
0.7 0.898 0.851 0.976 0.940 0.684 0.734 0.711 0.636 0.504 0.640
0.6 1.000 0.990 1.000 0.996 0.948 0.960 0.957 0.860 0.784 0.922
Table 3.2 shows results when the treatment effect is delayed by 6 months. The
first row, with α = 1, again shows that type I error rates are near the nominal level
of 0.05, although the logrank test for time-to-first-event is somewhat high. When the
events are uncorrelated, the area under the τ -RMRL test and the proportional rates
model are most powerful among the alternatives. The power of T∗ is similar to that
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of TGL, followed distantly by TLR, which suffers the most from the delayed treatment
effect since it uses the time-to-first-event.
In the correlated event case, the area under the τ -RMRL test has the highest
power, followed by T∗, while the remaining tests drop in power anywhere from 30-
40%. The tests that assume proportional rates suffer somewhat from violation of
the assumption in this scenario, in addition to the influence of the correlated data
structure on power.
Table 3.2: Power of two-sample hypothesis tests in 500 Monte Carlo simulations for
scenario two where we assume proportional hazards in the two treatment
groups but that treatment is only effective after a latency period.
ρ1 = 0, ρ2 = 0 ρ1 = 0.5, ρ2 = 0.3
α T∗ TR TPM TGL TLR T∗ TR TPM TGL TLR
1.0 0.042 0.045 0.058 0.042 0.072 0.052 0.056 0.062 0.046 0.056
0.9 0.112 0.142 0.144 0.134 0.068 0.084 0.098 0.072 0.058 0.062
0.8 0.344 0.391 0.396 0.326 0.120 0.212 0.295 0.168 0.114 0.132
0.7 0.688 0.741 0.744 0.618 0.206 0.476 0.563 0.342 0.228 0.270
0.6 0.934 0.966 0.956 0.898 0.342 0.736 0.856 0.544 0.396 0.404
Table 3.3 shows results when the treatment effect vanishes after 12 months. With
uncorrelated events, type I error rates are slightly inflated for all tests, although
this pattern was not seen in the correlated scenario. In either correlation setting,
the time-to-first event analysis has the greatest power compared to all the recurrent
event analyses. The recurrent event testing procedures, that use additional follow-up
information beyond the first combined-event, add statistical noise without sufficient
statistical signal towards the end of follow-up. The area under the τ -RMRL test is
especially sensitive to loss of treatment effect over time. This is perhaps the only
scenario where the time-to-first event analysis is clearly preferred.
In Appendix B.6, we include plots of the empirical mean 12-month RMRL for
group 1 and for each value of alpha for group 2 for each of the scenarios.
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Table 3.3: Power of two-sample hypothesis tests in 500 Monte Carlo simulations for
scenario 3 where we assume short duration treatment effect.
ρ1 = 0, ρ2 = 0 ρ1 = 0.5, ρ2 = 0.3
α T∗ TR TPM TGL TLR T∗ TR TPM TGL TLR
1.0 0.068 0.083 0.070 0.074 0.064 0.048 0.043 0.058 0.054 0.050
0.9 0.070 0.067 0.082 0.084 0.084 0.058 0.057 0.076 0.052 0.064
0.8 0.152 0.093 0.220 0.218 0.230 0.092 0.068 0.130 0.096 0.186
0.7 0.278 0.153 0.376 0.370 0.414 0.162 0.085 0.172 0.126 0.308
0.6 0.484 0.263 0.608 0.592 0.662 0.334 0.188 0.300 0.230 0.524
3.6 Example
The Azithromycin in COPD Trial (NACT) (Albert et al., 2011) randomized
chronic obstructive pulmonary disease (COPD) patients with a history of prior acute
exacerbations (AE) to receive either azithromycin or placebo for approximately 12-
13 months (380 days) to determine whether azithromycin reduced the frequency of
AE. The original study showed a significant benefit in the azithromycin group using
traditional methods for recurrent events. To make the example more interesting, we
restrict our attention to the first 380 randomized patients (n1 = 192 azithromycin,
n2 = 188 placebo), which corresponds to approximately one year of accrual, rather
than the full dataset with over 3 years of accrual and 1117 patients. The data includes
recurrent AE times as well as information on mortality and loss to follow-up over the
study period, with 511 observed total AE and mortality events spread throughout
the 380 days of follow-up.
The time to first event analysis gives a hazard ratio of 0.80 (95% CI: 0.62-1.03)
with a logrank test p-value of 0.085. The proportional means model recurrent event
analysis estimates the intensity rate ratio as 0.78 (95% CI: 0.61-0.99) with a p-value
of 0.045. The Ghosh & Lin test for recurrent events subject to death gives a p-value
of 0.131.
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We apply our testing procedure with τ = 250, where the follow-up window length
was chosen so that we could use two follow-up windows starting at days 0 and 130.
Limitations in the follow-up data precluded our ability to view several one-year follow-
up windows of treatment effect, which we would recommend for use with this statistic
in the design phase of a COPD study in the future. Follow-up window start times of
0 and 130 days follow recommendations in Section 3.4.3, with a slight adjustment to
ensure the entire follow-up period was used.
The estimated average time to event within the next 250 days across the follow-
up windows is 162 days in the placebo group and 179 days in the azithromycin
group, with a p-value of 0.030. The RMRL plot in Figure 3.1 indicates there may
be a decreasing treatment effect over time but overall there is a significant treatment
difference. The p-value of the testing procedure comparing the area under each of
these RMRL functions is 0.029.
3.7 Discussion
We have developed two recurrent event testing procedures that are better able to
detect treatment effects on a combined-endpoint when there are correlated recurrent
and terminating events and the treatment effect continues to manifest in later follow-
up periods (first two simulation scenarios). A consequence of correlation in event
times within an individual is a significant drop in power that will affect the viability
of study designs if not accounted for during the design stage. That is, a study
designed assuming independent gap times will be underpowered. A study powered
based on our proposed statistics with a reasonable correlation assumption would






















Figure 3.1: Restricted Mean Residual Life function evaluated for follow-up windows
of interest beginning at 0 and 130 days from randomization.
better than planned. In the case that events are not correlated and incidence rates
are proportional, the proportional means model is hard to beat, with power 10-20%
higher than its competitors (first simulation scenario).
Our presentation that analyzes combined death and recurrence endpoints assumes
that there is no interest in endpoint-specific treatment effects. When such interest
exists, a competing risk testing procedure would be preferred. In the flavor of a
competing risks analysis, our method can be applied to recurrent events data where
deaths are treated as independent censoring events of the recurrent event process.
Alternatively, our method can be applied to deaths without including recurrent events.
Ghosh & Lin (2000) consider the treatment effect on the recurrent and terminating
event types separately while acknowledging that patients who die cannot experience
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any further recurrent events. When analysis of the combined event is sufficient in
defining treatment effects, as is standard in the design of pulmonary clinical trials for
example, our procedure appears to be more powerful than the Ghosh-Lin method.
CHAPTER IV
STATISTICAL CONSEQUENCES OF A
SUCCESSFUL LUNG ALLOCATION SYSTEM –
RECOVERING INFORMATION AND
REDUCING BIAS IN MODELS FOR URGENCY
4.1 Summary
The national lung allocation system has reduced the number of waitlist deaths
by ranking transplant candidates based on a lung allocation score (LAS). The LAS
requires estimation of the 1-year restricted mean waitlist survival (urgency) based on
current prognosis. Patients are required to update risk factors every 6 months. Fewer
waitlist deaths and the systematic removal of candidates from the waitlist for trans-
plantation present statistical challenges that must be addressed when using recent
waitlist data. Multiple overlapping 1-year follow-up windows are used in a 1-year re-
stricted mean model that estimates patient urgency based on risk-factors at the start
of the window. Censored patients are multiply imputed by sampling from the inverse
probability of censoring (IPCW) adjusted survival estimate, within a risk set of pa-
tients still at-risk and with similar prognosis to the censored patient. In simulation
studies, we found that the multiple imputation procedure was able to produce unbi-
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ased parameter estimates with similar efficiency to those obtained if censoring had
never occurred. The analysis of 10,740 lung transplant candidates revealed that for
most risk factors incorporating additional follow-up windows produced more efficient
estimates.
4.2 Introduction
Since 2005, national lung allocation policy for those aged 12 and over has re-
lied on the statistical estimation of a lung transplant candidate’s 1-year restricted
mean lifetime without opportunity for transplant (urgency) and the number of days
to be gained in the next year if a transplant is offered immediately (benefit) (Egan
et al., 2006). The United Network for Organ Sharing (UNOS) is charged with col-
lecting and updating patient risk factors so that the lung allocation score (LAS)
that determines transplantation priority can change with a candidate’s prognosis. In
fact, patients are required to update their allocation factors every six months or be
penalized with a zero LAS value that effectively puts them at the end of the can-
didate list (OPTN Policy 3.7; http://optn.transplant.hrsa.gov/PoliciesandBylaws2/
policies/pdfs/policy 9.pdf).
One feature that was intentionally designed into the LAS was a lack of influence
of waiting time on a patient’s score. The allocation method that preceded the LAS
was based entirely on waiting time, with those waiting longer given higher priority for
transplantation. This influenced listing behavior to the extent that candidates would
enter the waitlist before being willing to accept an organ, just to accrue waiting time
in the event they needed a transplant later. This also resulted in a high number of
deaths among those who were too urgent to accrue the needed waitlist time to get to
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the top of the list.
In terms of statistical development and maintenance of the LAS, only risk factors
collected at a candidate’s entry into the waitlist have been been used to model urgency
to date and only the first year of follow-up after listing had been used for restricted
mean lifetime estimation. This reflects an unfortunate waste of statistical information
in a setting where fewer and fewer waitlist deaths are being observed, due in part
to the success of allocation to patients more likely to die. Additional information
on 1-year prognosis using windows of follow-up after listing would (1) potentially
improve efficiency of estimation from additional events occurring beyond 1 year and
(2) potentially expand the knowledge base of measured risk factors that progress
beyond the listing stage, increasing the applicability of urgency scores to those on the
waitlist beyond one year. This latter feature would be particularly useful since listing
recommendations tend to catch patients at a similar state of urgency at the time
these listing risk factors are collected, whereas patients progress at quite different
rates thereafter. There is also the statistical challenge of dependent censoring of
waitlist outcomes that are circumvented by a timely transplant intervention.
Gong & Schaubel (2013) model the distribution of survival time from a set of
specified calendar times, conditional on the risk factors measured at each specified
calendar time, through Cox-regression models. They account for dependent censor-
ing through inverse probability of censoring weights. An estimate of restricted mean
survival can be obtained from a Cox-regression model by integrating the estimated
survival curve over the follow-up window of interest. Since our interest lies in esti-
mation of a 1-year restricted mean survival, we have chosen to model the restricted
mean survival directly.
In this paper we develop a restricted mean model for transplant urgency that uses
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data from multiple follow-up windows during the listing period. Updated risk profile
information at the beginning of each follow-up window is used to predict outcomes
for the subsequent year. We extend a multiple imputation procedure developed by
Xiang et al. (2013) for dependently censored data to address issues of removal from
the lung candidate pool based on LAS values involving urgency. This, in turn, allows
us to take advantage of generalized estimating equation (GEE) (Liang & Zeger, 1986)
software to account for the particular flavor of correlation induced from incorporating
(overlapping) follow-up windows from the same patient. In addition, we consider an
inverse-weighted pseudo-observation approach, similar to that developed by Xiang
& Murray (2012), that also takes advantage of the GEE framework to account for
correlated follow-up information.
Methods are summarized in Section 4.3. Notation and the data structure induced
by using multiple follow up windows are described in Section 4.3.1. Motivation be-
hind use of GEE methods applied to imputed datasets in this setting are described in
Section 4.3.2. It will be convenient to have a working understanding of inverse prob-
ability of censoring weighted (IPCW) survival estimation, as described by Robins
(1993), as it plays an important role in our methodology. In Section 4.3.3, we briefly
review how to construct inverse weighted survival estimates that are consistent for
the survival function in the presence of dependent censoring. Our extension of the
pseudo-observation restricted mean model, which adjusts for dependent censoring as
in Xiang & Murray (2012), is described in Section 4.3.4. Methods for multiple im-
putation of dependently censored waitlist outcomes are described in Section 4.3.5.
Section 4.4 assesses our approach versus alternative approaches for estimating lung
candidate urgency via simulation. We then analyze a recent release of lung trans-
plant data collected by UNOS in Section 4.5, providing updated urgency measures in
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this cohort as well as evaluating urgency changes over time. A discussion follows in
Section 4.6.
4.3 Multiple Imputation Methodology
4.3.1 Notation
Failure and censoring times are denoted by Ti and Ci, respectively, for patient
i = 1, . . . , n. The observed event time is Xi = min(Ti, Ci) with associated failure
indicator variable δi = I(Ti < Ci). Vi(t) and Zi(t) are covariates affecting Ci and
Ti, respectively. We denote the recorded histories of Vi(t) and Zi(t) up to time t
by V̄i(t) = {Vi(u); 0 ≤ u ≤ t} and Z̄i(t) = {Zi(u); 0 ≤ u ≤ t}, respectively. The
event counting process is defined as Ni(t) = I(Xi ≤ t, δi = 1) and the at-risk process
is defined as Yi(t) = I(Xi ≥ t). We also define the counting process for censoring,
NQi(t) = I(Xi ≤ t, δi = 0).
Our proposed method incorporates information from several follow-up windows
of length 1 year, spaced 6 months apart; i.e., windows start at {0, 6, 12, ...} months
until removal from the candidate list for transplantation. More generally, windows of
length τ start at times {t1, . . . , tni}, ni = 1, . . . , b, i = 1, . . . , n. For individuals with
available follow-up during a window starting at t, we define T ∗i (t) = min(Ti− t, τ) as
the restricted time to event from t, where τ = 1 year in the lung allocation setting
but otherwise it may be any value where P (Ci > τ) > 0. We will estimate candidate
urgency using data pairs {T ∗i (t1),Zi(t1)}, {T ∗i (t2),Zi(t2)}, . . . , {T ∗i (tni),Zi(tni)} , i =
1, ..., n via the model
E[log{T ∗i (tj)}] = βTZi(tj). (4.1)
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In Figure 4.1 we illustrate the relationships between Ti, T
∗
i (t) and Zi(t) for t =
0, 6, 12 and 18 months. In our first example, patient 1 dies at 20 months post
listing (T1 = 20). Hence patient 1 contributes information on one year survival via
the data pairs {T ∗1 (0) = 12 months,Z1(0)}, {T ∗1 (6) = 12 months,Z1(6)}, {T ∗1 (12) =
8 months,Z1(12)}, and {T ∗1 (18) = 2 months,Z1(18)}. Patient 2 is has T2 = 7 months
and is therefore observed for two follow-up windows with start times {0, 6} and cor-
responding data pairs {T ∗2 (0) = 7 months,Z2(0)} and {T ∗2 (6) = 1 month,Z2(6)}.
Patient 3 was transplanted at C3 = 7 months and is therefore also observed for two
follow-up windows with start times {0, 6}. In Section 4.3.5, we describe a multi-
ple imputation procedure for missing failure times that will be used in our analysis.
Hence, if a failure time of 10 months is imputed for patient 3, this patient would
contribute data pairs {T ∗3 (0) = 10 months,Z3(0)} and {T ∗3 (6) = 4 months,Z3(6)} to
the analysis for one of the M multiply imputed datasets.
4.3.2 Generalized estimating equations for complete data
Once we have constructed the longitudinal data structure as described in Sec-
tion 4.3.1, the correlation between observations from different follow-up windows
within each patient must be accounted for when fitting model (4.1). GEE provides a
framework that easily allows the correlation between overlapping and non-overlapping
follow-up windows to differ via the unstructured working correlation matrix. In ad-
dition, the robust sandwich variance provides protection against misspecification of
working correlation matrix. The wider availability of correlation matrices makes
GEE software ideal. Currently available statistical software for correlated censored
survival outcomes assumes that correlated event times follow an exchangeable corre-
lation structure between any two pairs of outcomes that doesn’t accommodate our
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Figure 4.1: Example of how to construct the random variables T ∗i (t) = min{Ti(t), 12}
in each of the follow-up windows for which the patients are under obser-
vation in three cases. Patient 1 dies at 20 months post-listing; patient 2
dies at 7 months post-listing; and patient 3 is transplanted at 7 months
post-listing with one of their M imputed death times equal to 10 months.
data well. For example, the overlapping follow-up windows should have a different
correlation structure than the windows that do not overlap.
4.3.3 IPCW Survival Estimation
The method to construct inverse weighted survival estimates, ŜWT (t), that are
consistent for the survival function, ST (t), in the presence of dependent censoring
proceeds as follows. First we fit a Cox model for censored outcomes via the model,
λQ{t|V̄ (t)} = λQ0(t) exp{γTV(t)},
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where λQ{t|V̄ (t)} = lim∆t→0 P{t ≤ Xi < t + ∆t, δi = 0|Xi ≥ t, V̄ (t)}/∆t is the
hazard function for the censoring distribution that depends on the recorded history
of covariates V̄ (t) via a proportional hazards model and λQ0(t) is an unspecified
baseline hazard for the censoring distribution. The parameters from the model, γ,
are consistently estimated by γ̂ and the estimates can be obtained using most standard
statistical software.
For each patient i = 1, . . . , n, we define KVi (u) = P{Ci > u|V̄i(u)} based on the
























and the IPCW survival estimate adjusted for dependent censoring captured by V(t)
becomes ŜWT (t) = exp{−Λ̂WT (t)}.
4.3.4 Restricted Mean Model via Pseudo Observations Adjusted for De-
pendent Censoring
Andersen et al. (2004) developed a pseudo observation approach to modeling (4.1)
that was later extended by Xiang & Murray (2012) to account for dependent cen-
soring through incorporating inverse weighted survival estimates described in Section
4.3.3. Although pseudo observation methods sometimes struggle with intercept bias
in small samples, resulting restricted mean estimates are useful in defining risk sets for
imputation since these sets are invariant to intercept estimation. These models also
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have the advantage of being extremely easy to implement. With the ultimate goal of
defining risk sets that will be used in our imputation procedure, we now summarize
how to estimate pseudo observations from each follow-up window.
For each patient i = 1, . . . , n at each time tj where j = 1, . . . , ni, the pseudo-
observation is defined to be
PO ij = nj δ̂j − (nj − 1)δ̂−ij (4.2)
where nj is the number of patients at-risk at time tj, and δ̂j and δ̂
−i
j are estimates
of E[log{T ∗i (tj)}] based on datasets with and without patient i, respectively. The




log(u)dP (Ti − tj > u|Ti > tj) + log(τ)P (Ti − tj > τ |Ti > tj).
The estimate of P (Ti − tj > u|Ti > tj) from the entire dataset is given by
P̂ (Ti − tj > u|Ti > tj) =
ŜWT (tj + u)
ŜWT (tj)
and the estimate of P (Ti− tj > u|Ti > tj) from the dataset without patient i is given
by
P̂ (−i)(Ti − tj > u|Ti > tj) =
Ŝ
W (−i)





























log(u)dP̂ (−i)(Ti − tj > u|Ti > tj) + log(τ)P̂ (−i)(Ti − tj > τ |Ti > tj),
inserting these into equation (4.2) to obtain PO ij, i = 1, . . . , n and j = 1, . . . , ni.
GEE methodology applied to data pairs {PO ij,Zi(tj)}, i = 1, . . . , n and j = 1, . . . , ni
give us model (4.1) parameter estimates, β̂PO
W
.
4.3.5 Outline of Multiple Imputation Algorithm
Each censored patients’ current follow-up window has measured covariates Z(tni)
and a censored event time C(tni) = min(Ci− tni , τ) that requires multiple imputation
for generation of convenient complete datasets for analysis. Several authors have
suggested methods for multiple imputation in the presence of dependent censoring
including Faucett et al. (2002); Hsu et al. (2006); Liu et al. (2011); Xiang et al. (2013).
Our approach extends that used by Xiang et al. (2013) to the setting with multiple
follow-up windows, and hence is able to take advantage of time-dependent covariates
available at the beginning of each window in model (4.1)’s restricted mean estimation.
While Xiang et al. (2013) were able to use time-dependent covariates in forming risk
sets similar to what we propose in the following, they were not able to incorporate
updated covariate information directly into their restricted mean model.
Inverse Transform Imputation
The simplest case of the inverse transform imputation method is based on a
Kaplan-Meier estimate, ŜT (t), that is consistent for the survival function, ST (t). In
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this case, Taylor et al. (2002) showed that multiple imputation reproduces the the
Kaplan-Meier on average. We review this simplest case to avoid notation in delivering
the concept. Our proposed multiple imputation method follows the same procedure
with a different risk set definition for Ri and a different consistent survival estimate
that accounts for dependent censoring within the risk set, ŜWT ∗i (tni )
(t|Ri), both of which
will be given in later in Section 4.3.5.
For a patient censored at Ci, Taylor et al. (2002) generate imputes by sampling
from the distribution with survival function ST (t|T > Ci). Since ST (t|T > Ci) is
not a known function, it is consistently estimated with ŜT (t|T > Ci) in applying
the inverse transform. The impute, t, is sampled by (1) generating a Uniform(0,1)
random variable, u, and (2) finding the smallest value t where ŜT (t|T > Ci) ≤ u.
The risk set, Ri, is defined as the set of patients with comparable risk to the patient
censored at Ci and in this simple case it is comprised of patients with Tj > Ci for
j = 1, . . . , n. Step (2) can be equivalently expressed as finding the smallest value t
where ŜT (t|Ri) ≤ u when using risk set notation.
Hsu et al. (2006) extended this algorithm to more complicated risk set, Ri, com-
prised of patients with similar survival and censoring hazard estimates. Liu et al.
(2011) use restricted mean models in defining risk sets and recommend sampling
from the distribution of the residual of the restricted mean model when forming an
impute. Xiang et al. (2013) further extended this algorithm to the use of ŜWT (t) in
the inverse transform method.
In our setting, we impute for an individual censored at Ci(tni) < τ where imputes
are sampled from the survival distribution of T ∗i (tni) within the risk set, Ri. The
impute, t, is sampled by (1) generating a Uniform(0,1) random variable, u, and (2)
50
finding the smallest value t where ŜWT ∗i (tni )
(t|Ri) ≤ u. Then by (3) identifying the
observed event time, T ∗k (tni), that corresponds to t, we can solve for the associated
residual ε using model (4.1) where log{T ∗k (tni)} = β̂PO
WTZk(tni) + ε. Lastly, (4) if
t = τ then impute T̃ ∗i (tni) = τ , otherwise impute T̃
∗
i (tni) = exp{β̂PO
WTZi(tni) + ε}.
If T̃ ∗i (tni) < Ci(tni) then sample another t and repeat steps (3) and (4) until the
imputed value is greater than Ci(tni).
Risk Set Formation
As in the simplest case of risk set formation, the minimal constraint for belonging
to Ri is Tk > Ci, k = 1 . . . , n. Further restrictions based on information from Zi(t)
improve similarity of patients in the risk set to the censored individual being imputed.
The covariates Zi(t) are related to survival and we can improve our imputation by
selecting patients with similar urgency at the censoring time Ci based on our linear
model (4.1). The second constraint for belonging to risk setRi is then |β̂PO
WTZk(Ci)−
β̂PO
WTZi(Ci)| < ε where ε is the parameter that controls how closely the linear
predictors should match at Ci. The choice of epsilon is based on defining a risk set
large enough to produce valid multiple imputes but as homogenous as possible with
respect to urgency. In addition we require that patient k is in the same diagnosis
group as patient i and that LASk(Ci) = LASi(Ci) so that patients have similar
urgency and transplant probability.
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Inverse Weighted Survival Estimation Within Risk Set
Within the risk set, the inverse probability of censoring weight for the kth patient
is defined as








Then the inverse weighted survival estimate within the risk set is ŜWT ∗i (tni )
(t|Ri) =
exp{−ΛWT ∗i (tni )(u|Ri)} for Ci(tni) ≤ u < τ and Ŝ
W
T ∗i (tni )
(t|Ri) = 0 for u > τ where
Λ̂WT ∗i (tni )












Analysis of the M multiply imputed datasets
We repeat the imputation procedure until we obtain M completed datasets. In
practice M=10 is usually sufficient to produce valid results. The analysis of the M
multiply imputed datasets is given by Little & Rubin (1986). For each complete
dataset, we can construct the longitudinal data structure described in Section 4.3.1.
Model (4.1) GEE parameter estimates for dataset m are denoted by β̂MIm and their
associated variance estimates are denoted by V̂ ar(β̂MIm ), m = 1, . . . ,M .





The associated variance estimate is V̂ ar(β̂MI) = W + (1 + M−1)B, where W =∑M
m=1 V̂ ar(β̂
MI






β̂MI)2/(M − 1) is the between imputation variance. The 95% confidence intervals
and hypothesis tests for β̂MI are constructed based on the asymptotic distribution
(β̂MI − β)/
√
V ar(β̂MI) ∼ tν . The degrees of freedom of the t-distribution are given
by ν = (M − 1)[1 +W/{B(M + 1)}]2.
4.4 Simulations
In order to better understand finite sample behavior of our methods in relation to
other available approaches, we summarize simulation results from 500 Monte Carlo
iterations with n = 300 patients. Each iteration gives GEE parameter estimates
for the model, E(log[min{Ti(tj), τ}]) = β0 + β1 × Z1i(tj) + β2 × Z2i, via (a) the
IPCW pseudo observation method applied to the first follow-up window as in Xiang
& Murray (2012), (b) Xiang, Murray and Liu’s multiple imputation method applied
to the first follow-up window as in Xiang et al. (2013) and (c) our proposed multiple
imputation method that incorporates information from multiple follow up windows.
As a benchmark we also present results (d) in the absence of censoring when multiple
follow up windows are used in estimation. Each method assumes τ = 1 year. Methods
using follow-up beyond year one in estimation incorporate information from 1-year
windows starting at t1 = 0, t2 = 6 months and t3 = 12 months. The data are
generated as follows.
Step 1 : A time-dependent covariate, Z1i(tj), is simulated from a Uniform(0,1) at
t1 = 0, t2 = 6 months and t3 = 12 months. It will be convenient to denote the history
of this time-dependent covariate by Z̄1i(t) = {Z1i(u); 0 ≤ u ≤ t}. A time-independent
covariate Z2i is simulated from a Uniform(0,0.8).
Step 2 : Each failure time Ti is simulated from a piecewise exponential distribution
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with hazard equal to λi1 in the interval [0, 6], λi2 in the interval (6, 12] and λi3 in the









log(u)dP{Ti − tj > u|Ti > tj, Z̄1(u+ tj), Z2}
+ log(τ)P{Ti − tj > τ |Ti > tj, Z̄1(τ + tj), Z2},
where setting the above equal to the restricted mean model, β0 + β1Z1i(tj) + β2Z2i
gives us a way to solve for patient specific hazards. In Appendix C.1, we give further
details on the algebra involved.
Step 3 : The dependent censoring time Ci is generated from the piecewise expo-
nential distribution with hazard λCi (u) = λ
C
0 (u) exp{0.3Z1i(0) + 0.35Z1i(6)I(u > 6) +
0.01Z1i(0)Z1i(6)I(6 < u ≤ 12)+0.4Z1i(12)I(u > 12)+0.001Z1i(0)Z1i(6)Z1i(12)I(u >
12) + 0.1Z2i} where λC0 (u) is equal to 0.01 in the interval [0, 6], 0.011 in the interval
(6, 12] and 0.012 in the interval (12,∞), producing approximately 25% censoring prior
to 24 months.
Table 4.1 presents the results under the null hypothesis with β0 = 2.1, β1 = 0
and β2 = 0 and when covariates affect survival with β0 = 2.1, β1 = −0.125 and
β2 = 0.1. For each of the parameters we present the empirical mean, bias, empirical
mean standard error, empirical standard deviation and coverage of the 95% confidence
interval for each of the analysis approaches under consideration.
Based on the results in Table 4.1, we observe that the parameter estimates from
all methods have minimal bias under both the null hypothesis and for non-zero β’s,
except for the intercept term in the IPCW pseudo observation method. Several au-
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thors have noted issues with intercept bias for pseudo observation methods (Andrei
& Murray, 2007; Xiang & Murray, 2012). Low bias for β1 and β2 was also seen when
pseudo observation regression methods were applied to data from multiple follow-up
windows as described in Section 4.3.4 (data not shown), with β0 underestimated to
a similar degree. Hence, pseudo-observation methods seem useful for describing mul-
tiplicative effects of risk factors on the restricted mean and forming comparable risk
sets of patients, but tend to underestimate restricted means compared to imputation
methods with even moderate sample sizes.
Inclusion of follow-up windows starting at t2 = 6 and t3 = 12 months results in
more efficient estimates. The asymptotic relative efficiency (ARE) of our proposed
method versus the IPCW pseudo observation method is between 3.86 and 6.49 for each
of the parameters. The ARE of our proposed method versus the multiple imputation
method of Xiang and Murray is between 1.85 and 2.71. The ARE comparing our
proposed method with versus without censoring is between 0.95 and 1 indicating
that our method effectively handles dependent censoring and produces parameter
estimates with nearly the same efficiency as if censoring never occurred.
4.5 Example
The lung waitlist consists of 10,740 transplant candidates aged 12 years and older
who were newly listed between September 1, 2006 and March 2, 2012; 7,359 of these
patients received a transplant, 884 died while on the waitlist, 1,124 dropped off the
waitlist without a transplant and 1,373 were alive on the waitlist on March 2, 2012.
Risk factors used to model LAS urgency are given by the OPTN Thoracic Committee
(OPTN Policy 3.7) and have been vetted as worthy of inclusion in the algorithm. Most
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Table 4.1: Comparison of estimates from model based on one follow-up window
the IPCW pseudo-observation (IPCW-PO) and the multiple imputation
method (MI); based on three follow-up windows using uncensored obser-
vations (Uncensored) and our multiple imputation method (MI*) under
two scenarios with 500 Monte Carlo simulations. M=10 in both multiple
imputation methods.
Parameter IPCW-PO MI Uncensored MI*
β0 = 2.1 1.753 2.152 2.121 2.101
[-0.347, 0.182, [0.052, 0.119, [0.021, 0.079, [0.001, 0.081,
0.170, 0.546] 0.113, 0.940] 0.080, 0.920] 0.080, 0.950]
β1 = 0 -0.022 -0.010 -0.000 0.001
[-0.022, 0.238, [-0.010, 0.156, [-0.000, 0.093, [0.001, 0.097,
0.237, 0.950] 0.153, 0.950] 0.092, 0.958] 0.093, 0.962]
β2 = 0 -0.004 -0.007 -0.000 -0.002
[-0.004, 0.298, [-0.007, 0.196, [-0.000, 0.134, [-0.002, 0.142,
0.292, 0.928] 0.199, 0.964] 0.143, 0.940] 0.143, 0.956]
β0 = 2.1 1.715 2.150 2.126 2.107
[-0.385, 0.183, [0.050, 0.122, [0.026, 0.081, [0.007, 0.083,
0.181, 0.436] 0.121, 0.930] 0.079, 0.940] 0.081, 0.948]
β1 = −0.125 -0.142 -0.121 -0.123 -0.117
[-0.017, 0.240, [0.004, 0.160, [0.002, 0.097, [0.007, 0.100,
0.245, 0.952] 0.166, 0.928] 0.095, 0.962] 0.097, 0.958]
β2 = 0.1 0.164 0.096 0.090 0.085
[0.064, 0.300, [-0.004, 0.199, [-0.001, 0.143, [-0.015, 0.145,
0.285, 0.956] 0.197, 0.954] 0.145, 0.946] 0.145, 0.946]
Empirical Mean
[Bias, Empirical Mean Standard Error,
Empirical Standard Deviation, Coverage of 95% Confidence Interval]
have proven historical statistical significance in at least one previous analysis of lung
candidate data.
Patients are divided into four overarching diagnosis groups, A through D, by the
OPTN Thoracic Committee that are considered to be similar with respect to waitlist
and post-transplant survival. The details of the diagnoses that comprise each group
are given in OPTN Policy 3.7. In our dataset at listing, of the 3618 patients in Group
A, 2924 (81%) were diagnosed with chronic obstructive pulmonary disease; in Group
B, 262 (56%) out of 468 were diagnosed with primary pulmonary hypertension; in
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Group C, 1284 (99%) out of 1296 were cystic fibrosis patients; and in Group D, 3633
(68%) out of 5358 patients were diagnosed with idiopathic pulmonary fibrosis. A
few group A and D diagnoses are allowed to enter the urgency model as their own
risk factors. For group A, these are bronchiectasis, lymphangioleiomyomatosis and
sarcoidosis with PA mean≤30mm Hg. For group D, these are obliterative bronchioli-
tis, pulmonary fibrosis other and sarcoidosis with PA mean>30mm Hg. Eisenmenger
syndrome, from group B, is also listed as a risk factor in LAS. Most of these smaller
diagnosis groups are not statistically different from their larger conglomerate group
designation, but having a separate parameter has been important in obtaining public
approval of the algorithm.
In Table 4.2, we summarize the risk factors at listing within each of the four di-
agnoses groups. These factors are age, body mass index (BMI), cardiac index prior
to any exercise, central venous pressure (CVP) at rest, whether they were on contin-
uous mechanical ventilation, serum creatinine, whether they were diabetic, percent
predicted forced vital capacity (FVC), whether they required assistance with the ac-
tivities of daily living (ADL), O2 requirement at rest needed to maintain adequate
oxygen saturation, partial pressure of carbon dioxide (PCO2), pulmonary artery (PA)
systolic pressure at rest, and six minute walk distance obtained while receiving sup-
plemental oxygen to maintain oxygen saturation of 88% or greater at rest. Those
familiar with the LAS may recall that bilirubin has recently been approved as an ur-
gency risk factor. However, this measure has only recently started being collected by
the OPTN and was unavailable in the March 2012 release data used for our analyses.
Patients in group C are on average the youngest transplant candidates (mean age
is 29.4 years) and this is expected since the group consists almost entirely of patients
with cystic fibrosis, a genetic disorder that results in lung disease from a very young
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age. The main diagnoses in the other groups are lung diseases that develop over time
so most patients are older when they require a lung transplant. Having a cardiac
index less than 2 L/min/m2 is considered to be an indicator that the heart is not
functioning well. Based on this measure, patients in group B tend to be the most
severely ill with 17.5% of the patients having a cardiac index < 2 L/min/m2. The
proportion of patients requiring continuous mechanical ventilation is highest in group
C (6.3%) and lowest in group A (0.7%). FVC % predicted is a measure of lung
function and in terms of this measure the diagnoses groups are ranked C, D, A and
B from most severely ill to least severely ill. However the patients in group C are
also most likely to need no assistance with activities of daily living (19.2%) and are
able to walk much long distances in the six minute walk test compared to the other
groups. Group B consists of patients with various hypertensive disorders and as we
would expect, patients in this group have the highest average PA systolic pressure at
rest (76.7 mm Hg).
As urgent patients receive transplants, they are removed from the waitlist. This
systematic removal of patients creates a problem of dependent censoring that we
adjust for using inverse probability of censoring weights in the survival estimation
procedure discussed in Section 4.3.3. For each patient on the waitlist the probability
of being censored is estimated from a time-dependent Cox model, the results of which
are presented in Table 4.3. The covariates that influence censoring are gender, race
(white, black and other), height, blood type (A, B, O and AB) and time-dependent
LAS and listing status (active and inactive). Gender, race and height are all seen to
be highly significant characteristics for differentiating which patients will be censored.
Blood types A and B were observed to be similar in terms of censoring hazard but
patients with blood type O had a lower hazard of censoring compared to blood type A
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(hazard ratio=0.96, 95% confidence interval: 0.92-1.00) and patients with blood type
AB had a higher hazard of censoring compared to blood type A (hazard ratio=1.12,
95% confidence interval: 1.00-1.25). Patients with an LAS of 0 have the lowest
possible score with a very low chance of transplant (censoring) that gets ameliorated
a bit by geography when higher risk patients are not in competition for an organ. A
one-unit increase in LAS when the 0<LAS≤30 results in a decreasing hazard which
reflects the low probability of being offered a transplant for low LAS scores. The effect
of a one unit increase in LAS decreases for higher ranges of LAS scores. This may
seem counterintuitive however the probability of being censored is counterbalanced
by the probability of surviving until a transplant becomes available.
Figure 4.2 compares the IPCW survival estimate of waitlist survival to the Kaplan-
Meier estimate of waitlist survival from listing up to three and a half years post
listing. The Kaplan-Meier estimate does not adjust for dependent censoring resulting
from transplantation and therefore estimates higher waitlist survival probabilities
compared to the IPCW survival.
Using the IPCW survival estimate, we construct IPCW pseudo-observations for
1-year follow-up windows starting at 0, 6, 12, 18, 24 and 30 months following the
method described in Section 4.3.4. The start time of the final follow-up window was
chosen to ensure we had at least 25 risk set deaths in each follow-up window. The
pseudo-observations are used to fit model (4.1) to estimate lung candidate urgency
based on LAS risk factors. The parameter estimates are then used in the multiple
imputation procedure presented in Section 4.3.5.
In Table 4.4 we present the results of fitting the restricted mean model to estimate
lung candidate urgency using three different methods, (a) the IPCW pseudo observa-
tion method applied to the first follow-up window as in Xiang & Murray (2012), (b)
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Xiang, Murray and Liu’s multiple imputation method applied to the first follow-up
window as in Xiang et al. (2013) and (c) our proposed multiple imputation method
that incorporates information from multiple follow up windows. The exponentiated
parameters (eβ̂), 95% confidence intervals and p-values are presented for each risk fac-
tor and are therefore interpreted in terms of their multiplicative effect on the number
of days lived in the next year.
The intercept estimated from the IPCW pseudo-observation (IPCW-PO) method
has a very wide confidence interval indicating that it is not estimated well. All
the effect size confidence intervals from the IPCW-PO method are wider than those
obtained using the multiple imputation method applied to the first follow-up window.
In general, the conclusions reached regarding statistically significant risk factors are
the same even if the effect sizes differ between the two methods. The exceptions
include having a cardiac index<2.0 L/min/m2 and PA systolic pressure in group B,
C or D.
Our proposed multiple imputation procedure estimates the effect of the risk fac-
tors across the 6 follow-up windows viewed during the 3.5 years since listing. Hence,
our parameter estimates should be comparable to the other methods if time since
listing does not play a strong role. Again, the intercept was the most different be-
tween our proposed method and the others, approximately 18 days smaller than the
multiple imputation method based on only the first follow-up window. Our proposed
method gave shorter confidence intervals compared to the other methods indicating
increased efficiency resulting from the incorporation of additional follow-up windows.
Comparing the two multiple imputation procedures, we observe that time since listing
does not play a role and the effect sizes remain similar. The additional information
contained in later follow-up windows allows us to confirm the statistical significance
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of some of the risk factors including CVP in group B, being a diabetic and PCO2.
Table 4.2: Summary of LAS urgency covariates at listing, by diagnosis group, in
10,740 lung transplant candidates†.
Group A Group B Group C Group D
LAS Covariates n=3618 n=468 n=1296 n=5358
Age (years) 58.1 (8.3) 45.7 (14.7) 28.4 (10.3) 57.1 (11.0)
BMI (kg/m2) 24.6 (4.3) 25.1 (4.7) 19.3 (2.9) 27.0 (4.4)
Cardiac Index<2.0 (L/min/m2) 150 (4.1%) 82 (17.5%) 16 (1.2%) 271 (5.1%)
CVP (mm Hg) 7.7 (4.2) 10.8 (6.5) 5.2 (3.8) 5.5 (4.3)
Continuous Mechanical Ventilation 26 (0.7%) 10 (2.1%) 82 (6.3%) 196 (3.7%)
Creatinine (serum mg/dL) 0.8 (0.2) 1.0 (0.6) 0.7 (0.3) 0.9 (0.3)
Diabetes 430 (11.9%) 64 (13.7%) 627 (48.4%) 1249 (23.3%)
FVC (% predicted) 54.0 (17.5) 66.4 (22.7) 40.0 (11.8) 47.6 (17.0)
No assistance with ADL 368 (10.2%) 32 (6.8%) 249 (19.2%) 506 (9.4%)
O2 requirement at rest (L/min) 3.0 (2.5) 4.0 (4.4) 2.9 (3.5) 4.9 (5.2)
PCO2 (mm Hg) 49.9 (10.8) 42.4 (6.4) 53.4 (17.4) 44.7 (8.2)
PA systolic (mm Hg) 38.3 (10.8) 76.7 (25.7) 39.0 (10.6) 43.2 (16.2)
Six-min walk distance (feet) 783.4 (347.9) 776.7 (438.4) 970.6 (465.8) 797.2 (464.2)
† For continuous variables, numbers shown are mean (standard deviation)
For binary variables, numbers shown are number (proportions)
Body Mass Index (BMI); Cardiac Index (CI); Central Venous Pressure (CVP)
Activities of Daily Living (ADL); Pulmonary Artery (PA)
4.6 Discussion
LAS implementation has successfully reduced waitlist deaths, which reflects vitally
important improvements for end stage lung disease care. This same reduction in
deaths results in less power to estimate waitlist survival in current cohorts. It is
therefore critical to develop statistical methodology that is able extract as much
information as possible from available data.
As we saw in Section 4.5, incorporating additional follow-up windows to estimate
transplant urgency resulted greater efficiency, as evidenced by narrower confidence
intervals for parameter estimates. We were also able to confirm that low central
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Table 4.3: Proportional hazards censoring model for 10,740 lung transplant candi-
dates
Hazard Ratio 95% Confidence Interval p-value
Time-independent characteristics
Female (vs Male) 0.76 (0.72,0.80) < 0.0001
Black (vs White) 0.77 (0.72,0.83) < 0.0001
Other (vs White) 0.77 (0.72,0.83) < 0.0001
Height: < 5′3′′ (versus > 5′9′′) 0.63 (0.58,0.68) < 0.0001
Height: 5′3′′-5′6′′ (versus > 5′9′′) 0.78 (0.73,0.83) < 0.0001
Height: 5′6′′-5′9′′ (versus > 5′9′′) 0.87 (0.82,0.92) < 0.0001
Blood type: B (versus A) 1.00 (0.93,1.07) 0.9285
Blood type: O(versus A) 0.95 (0.91,0.99) 0.0134
Blood type: AB (versus A) 1.12 (1.00,1.25) 0.0473
Time-dependent characteristics
LAS> 0 (versus LAS= 0) 2224 (22.14, > 3000) 0.0010
Unit increase in LAS: 0<LAS≤30 0.76 (0.65,0.88) 0.0004
Unit increase in LAS: 30<LAS≤35 1.14 (1.11,1.17) < 0.0001
Unit increase in LAS: 35<LAS≤40 1.11 (1.09,1.12) < 0.0001
Unit increase in LAS: 40<LAS≤60 1.04 (1.03,1.04) < 0.0001
Unit increase in LAS: LAS>60 1.03 (1.03,1.04) < 0.0001
Active vs inactive status 1.79 (1.65,1.95) < 0.0001
venous pressure remained a statistically significant risk factor for patients in diagnosis
group B for the current cohort. Measuring this risk factor is an invasive procedure so
it is important to reassure that its collection is useful for ranking patients.
By design, a patient’s LAS value does not change based on time-on-waitlist so that
there is no advantage to altering listing behavior to game the system and disadvantage
other patients. In our analysis we confirm that the effect sizes of most risk factors do
not depend on time-on-waitlist.
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Figure 4.2: Waitlist probability of survival estimated by the Kaplan-Meier method






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































The objective of this dissertation was to develop statistical methods for estima-
tion, hypothesis testing and regression models for the τ -restricted mean survival that
included follow-up information beyond τ . To this end, we chose to use multiple obser-
vation windows, of length τ , within the available follow-up period. When estimating
the restricted mean survival the additional follow-up windows produced more effi-
cient estimates. In the hypothesis testing procedure we were able to show that both
recurrent and terminating events could be included and this resulted in a more pow-
erful test compared to some commonly used approaches when the events are highly
correlated. The restricted mean regression models that we develop allow for time-
dependent covariates that are updated every 6 months. In each of the statistical
methods we have developed we approach the data from a different perspective and
incorporate follow-up from multiple observation windows, which allows us to use more
of the observed information.
In the Chapter II we introduced the overall τ -restricted mean survival that used
follow-up from multiple observation windows to improve precision when estimating
the τ -restricted mean survival. The correlated data structure resulting from the mul-
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tiple follow-up windows required a variance estimate that was able to better account
for the correlation structure than the sandwich estimator. We followed an approach
by Woodruff (1971) where the estimator was linearized using Taylor series in order
to identify independent sums of random variables using asymptotic arguments. We
advocate the use of the empirical variance of these independent sums when estimating
the variance of the overall τ -restricted mean survival. The closed form asymptotic
variance was also studied, which required understanding the relationship between
the event process and the at-risk process across follow-up windows within the same
patient. This was necessary in order to study how the number and spacing of the
follow-up windows affect the efficiency of the estimator. We found that the using over-
lapping follow-up windows spaced τ/2 months apart provided the greatest increase in
efficiency and that introducing follow-up windows more frequently resulted in greater
complexity but only minor gains in efficiency. The finite sample-size performance of
our estimator and proposed variance was compared to the sandwich variance and the
variance that assumes independence in a simulation study. The estimate of the overall
τ -restricted mean survival was unbiased and our proposed variance was better able
to account for the correlation structure resulting from multiple overlapping follow-up
windows compared to the sandwich variance.
The nonparametric hypothesis tests that we developed in Chapter III incorpo-
rated recurrent and terminating events beyond the first by combining time-to-first
event analyses in each of the follow-up windows. This approach was an attractive al-
ternative to the usual recurrent event analyses since it did not require any assumptions
regarding the correlation between the event times but allowed us to use information
beyond the initial event. We studied two methods of combining the follow-up win-
dows for two-sample testing procedures in a randomized trial. The first pooled the
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data in the same way as the overall τ -restricted mean survival in the previous chapter
and the second used the area under the τ -restricted mean residual life function. For
each test statistic we were able to describe the asymptotic distribution under the null
using the linearization technique of Woodruff (1971) without making any assump-
tions about the correlation between events. In simulation studies we found that when
events were correlated our methods outperformed the robust proportional rates model
of Lin et al. (2000) and the Ghosh & Lin (2000) test for recurrent events subject to
death. When events were uncorrelated, the proportional rates model was difficult
to beat. We also observed that correlated events resulted in a significant decrease
in the power. This observation has consequences for study design since a recurrent
events study that does not account for potential correlation between gap-times will
be underpowered if there is correlation. Our testing procedures were more powerful
when there is correlated data and could be used in study design to ensure the study
was sufficiency powered while accounting for potential correlation.
Chapter IV developed regression models for restricted mean survival that used
risk-factors measured at the start of each follow-up windows. This allowed us to in-
corporate information from time-dependent risk factors past baseline. Our aim was
to fit the LAS urgency model using time-dependent covariates. We extended work
by Xiang et al. (2013) to estimate the parameters from the model. For each censored
patient, we multiply imputed a time-to-event using the inverse transform method.
The impute was sampled from within a risk-set of patients with similar prognosis
to the censored patient but who were still at-risk. In the lung allocation setting, a
patient’s LAS score is one of the factors used to determine if they are offered a trans-
plant. The transplantation of severely ill patients resulted in dependent censoring
that we needed to account for in our methodology. We chose to use inverse probabil-
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ity of censoring weights to decrease the bias of the survival function estimate. The
complete data was then transformed into a longitudinal data structure. GEE was
used to estimate model parameters based on data pairs comprised of 1-year restricted
time-to-event from the start of the follow-up window and the risk-factors measured
at the start of the follow-up window. The differing correlation between overlapping
and non-overlapping follow-up windows was easily handled by GEE using an unstruc-
tured working correlation matrix with a robust sandwich variance to protect against
misspecification. Simulation studies showed that our method produced unbiased and
more efficient parameter estimates compared to methods which only used informa-
tion from the baseline observation window. The increased efficiency of our method
resulted in narrower confidence intervals for parameters in the LAS urgency model





Supplementary Materials for Chapter II
A.1 Convergence of estimator

























where λW (u) =
∑b
k=1 λ(tk, u)Pr{Xi(tk) ≥ u}/
∑b
l=1 Pr{Xi(tl) ≥ u}.
We use the following definitions from Section 2.4.2: {0 < T1 < . . . < TM < τ} are
observed event times from combined dataset; T0 = 0 and TM+1 = τ ; Fj{dN(Tj), Y (Tj)}
= dN(Tj)/Y (Tj); and Gm(F0, F1, . . . , Fm) = exp(−
∑m
j=0 Fj) with arguments of Fj




(Tm+1 −Tm)Gm(F0, F1, . . . , Fm).
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(Tm+1 −Tm) [ higher order terms] .
Term (A.1) is a non-stochastic numerical approximation of µ∗(τ) that converges
to µ∗(τ) as n→∞. Our convergence argument is complete upon showing
∑m
j=0{Fj−
λW (Tj)dTj} in (A.2) and (A.3) converges in probability to zero as n→∞.
Note that since
∑m





dN(u)/Y (u)− λW (u)du
}






converges in probability to zero as n→∞ to complete our convergence
argument.
It is convenient to first consider
∑n
i=1 Yi(u)/n, an empirical measure based on








∣∣∣∣∣ p→ 0 (A.4)































l=1 Pr{Xi(tl) ≥ u}
− 1∑b











l=1 Pr{Xi(tl) ≥ u}
−
∑b
k=1 λ(tk, u)Pr{Xi(tk) ≥ u}∑b




















dN(tk, u)− nλ(tk, u)Pr{Xi(tk) ≥ u}du
n
∑b






















dN(tk, u)− nλ(tk, u)Pr{Xi(tk) ≥ u}du
n
∑b









The first component of term (A.6) is a sum of b mean zero stochastic integrals with
respect to martingales. Using standard martingale theory, we derive the asymptotic







l=1 Pr{Xi(tl) ≥ u}
]2




λ(tk, u)Pr{Xi(tk) ≥ u}du
n
[∑b
l=1 Pr{Xi(tl) ≥ u}
]2 .
It is easily seen that the expression converges in probability to zero as n→∞. The
asymptotic covariance between any two of the b stochastic integrals associated with
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j=1 cov{dNi(tk, u), dNj(tl, v)}
n2[
∑b
l′=1 Pr{Xi(t′l) ≥ u}][
∑b






n cov{dNi(tk, u), dNi(tl, v)}
n2[
∑b
l′=1 Pr{Xi(t′l) ≥ u}][
∑b






E{dNi(tk, u)dNi(tl, v)} − E{dNi(tk, u)}E{dNi(tl, v)}
n[
∑b
l′=1 Pr{Xi(t′l) ≥ u}][
∑b




λ(tk, u)Pr{Xi(tk) ≥ u}I(0 ≤ u+ tk − tl ≤ s)du
n[
∑b
l′=1 Pr{Xi(t′l) ≥ u}][
∑b






λ(tk, u)Pr{Xi(tk) ≥ u}λ(tl, v)Pr{Xi(tl) ≥ v}du dv
n[
∑b
l′=1 Pr{Xi(t′l) ≥ u}][
∑b
l′=1 Pr{Xi(t′l) ≥ v}]
.
This expression also converges in probability to zero as n → ∞. Therefore the vari-
ance of the sum of the b stochastic integrals converges to zero and the first component
of term (A.6) converges in probability to zero. The second component of term (A.6)





dN(u)/Y (u)− λW (u)du
} p→ 0 as n → ∞ and we have completed
our convergence argument.
A.2 Asymptotic arguments for deriving the variance of the
proposed estimate
Continuing from Section 2.4.2, we need to show the following result about the






{Fj − λW (Tj)dTj}
]2
p→ 0.








dN(u)/Y (u)− λW (u)du
}]2
,





} p→ 0, hence we need only show that √n[∫ s
0
{dN(u)/Y (u) − λW (u)du}]
converges to a distribution with finite variance.

















dN(tk, u)− nλ(tk, u)Pr{Xi(tk) ≥ u}du
n
∑b











The first component of term (A.7) is the sum of b stochastic integrals and by the








l=1 Pr{Xi(tl) ≥ u}
]2




λ(tk, u)Pr{Xi(tk) ≥ u}du[∑b
l=1 Pr{Xi(tl) ≥ u}
]2 .
The asymptotic covariance between any two of the b stochastic integrals associated
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l′=1 Pr{Xi(t′l) ≥ u}][
∑b






n2 cov{dNi(tk, u), dNi(tl, v)}
n2[
∑b
l′=1 Pr{Xi(t′l) ≥ u}][
∑b






E{dNi(tk, u)dNi(tl, v)} − E{dNi(tk, u)}E{dNi(tl, v)}
[
∑b
l′=1 Pr{Xi(t′l) ≥ u}][
∑b




λ(tk, u)Pr{Xi(tk) ≥ u}I(0 ≤ u+ tk − tl ≤ s)du
[
∑b
l′=1 Pr{Xi(t′l) ≥ u}][
∑b






λ(tk, u)Pr{Xi(tk) ≥ u}λ(tl, v)Pr{Xi(tl) ≥ v}du dv
[
∑b
l′=1 Pr{Xi(t′l) ≥ u}][
∑b
l′=1 Pr{Xi(t′l) ≥ v}]
.
This expression is finite as n → ∞. Therefore the sum of the b stochastic integrals
has finite asymptotic variance.








k = 1, . . . , b, we note that each converges to a normal distribution with finite variance.
The covariance between any two terms associated with follow-up windows beginning














































dNi(tk, u)/n converges to a distribution with finite vari-
ance. By applying Slutsky’s theorem and (A.5), the second component of term (A.7)
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λW (u)du}] converges to a distribution with finite variance.
Next we show that the term (2.3d) from page 13 converges in probability to zero.
Once again we work with asymptotically equivalent stochastic integrals. The result















[Y (u)− E{Y (u)}]2E{dN(u)}
E{Y (u)}3
p→ 0







k=1 Pr{Xi(tk) ≥ u}][dN(u)− n
∑b
k=1 λ(tk, u)Pr{Xi(tk) ≥ u}du]
n2
[∑b









k=1 Pr{Xi(tk) ≥ u}]
∑b
k=1[dN(tk, u)− nλ(tk, u)Pr{Xi(tk) ≥ u}du]
n
[∑b









dN(tk, u)− nλ(tk, u)Pr{Xi(tk) ≥ u}du
n
[∑b
l=1 Pr{Xi(tl) ≥ u}
]2 .
By the martingale central limit theorem, each of the b terms converge to a mean zero
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The asymptotic covariance between any two of the b stochastic integrals associated















l′=1 Pr{Xi(t′l) ≥ u}]2[
∑b






n2 cov{dNi(tk, u), dNi(tl, v)}
n2[
∑b
l′=1 Pr{Xi(t′l) ≥ u}]2[
∑b






E{dNi(tk, u)dNi(tl, v)} − E{dNi(tk, u)}E{dNi(tl, v)}
[
∑b
l′=1 Pr{Xi(t′l) ≥ u}]2[
∑b




λ(tk, u)Pr{Xi(tk) ≥ u}I(0 ≤ u+ tk − tl ≤ s)du
[
∑b
l′=1 Pr{Xi(t′l) ≥ u}]2[
∑b






λ(tk, u)Pr{Xi(tk) ≥ u}λ(tl, v)Pr{Xi(tl) ≥ v}du dv
[
∑b
l′=1 Pr{Xi(t′l) ≥ u}]2[
∑b
l′=1 Pr{Xi(t′l) ≥ v}]2
.
This expression is finite as n→∞ and therefore the sum of the b stochastic integrals
has finite asymptotic variance. Applying (A.4) and Slutsky’s theorem, it can easily
be shown that term (i) converges in probability to zero.
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l=1 λ(tl, u)Pr{Xi(tl) ≥ u}
n2
[∑b










k=1 Pr{Xi(tk) ≥ u}
n
]2 ∑b
l=1 λ(tl, u)Pr{Xi(tl) ≥ u}[∑b










k=1 Pr{Xi(tk) ≥ u}
n
] ∑b
l=1 λ(tl, u)Pr{Xi(tl) ≥ u}[∑b












Yi(tk, u)− Pr{Xi(tk) ≥ u}
n
] ∑b
l=1 λ(tl, u)Pr{Xi(tl) ≥ u}[∑b












Yi(tk, u)− Pr{Xi(tk) ≥ u}
n
] ∑b
l=1 λ(tl, u)Pr{Xi(tl) ≥ u}[∑b
l′=1 Pr{Xi(tl′) ≥ u}
]3 du.
By the central limit theorem, each of the b summands converge in distribution to
a normal random variable with covariance between any two terms associated with
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×∑bl=1 λ(tl, u)Pr{Xi(tl) ≥ u}[∑b
l′=1 Pr{Xi(tl′) ≥ u}
]3

∑bl=1 λ(tl, v)Pr{Xi(tl) ≥ v}[∑b








n2 cov{Yi(tk, u), Yi(tl, v)}
n2
×∑bl=1 λ(tl, u)Pr{Xi(tl) ≥ u}[∑b
l′=1 Pr{Xi(tl′) ≥ u}
]3

∑bl=1 λ(tl, v)Pr{Xi(tl) ≥ v}[∑b








[E{Yi(tk, u)Yi(tl, v)} − E{Yi(tk, u)}E{Yi(tl, v)}]×∑bl=1 λ(tl, u)Pr{Xi(tl) ≥ u}[∑b
l′=1 Pr{Xi(tl′) ≥ u}
]3

∑bl=1 λ(tl, v)Pr{Xi(tl) ≥ v}[∑b








[Pr{Xi(tk) ≥ u,Xi(tl) ≥ v} − Pr{Xi(tk) ≥ u}Pr{Xi(tl) ≥ v}]×∑bl=1 λ(tl, u)Pr{Xi(tl) ≥ u}[∑b
l′=1 Pr{Xi(tl′) ≥ u}
]3

∑bl=1 λ(tl, v)Pr{Xi(tl) ≥ v}[∑b
l′=1 Pr{Xi(tl′) ≥ v}
]3
 du dv
Since the covariance terms are finite, the sum converges to a distribution with finite
variance and it can then be shown that term (ii) converges in probability to zero by
applying Slutsky’s theorem and (A.4).
A.3 Closed form asymptotic variance
The asymptotic closed form variance is useful for understanding design issues and
is defined in Section 2.4.2 on page 14. In this appendix we provide the details for the






















dNi(tk, u)− λW (u)Yi(tk, u)du∑b
l=1 Pr{Xi(tl) ≥ u}
]
ds.
Examining the variance more closely, we may simplify and expand terms.





























































dNi(tk, u)− λW (u)Yi(tk, u)du∑b
l′=1 Pr{Xi(tl′) ≥ u}
,
dNi(tl, v)− λW (v)Yi(tl, v)dv∑b
l′=1 Pr{Xi(tl′) ≥ v}
]
ds ds′(A.8)
The covariance that we need to calculate is based on correlated terms from patient i:
cov
{
dNi(tk, u)− λW (u)Yi(tk, u)du, dNi(tl, v)− λW (v)Yi(tl, v)dv
}
= E{dNi(tk, u)dNi(tl, v)} − λW (u)E{Yi(tk, u)dNi(tl, v)}du− λW (v)E{Yi(tl, v)dNi(tk,
u)}dv + λW (u)λW (v)E{Yi(tk, u)Yi(tl, v)}du dv − E
{




dNi(tl, v)− λW (v)Yi(tl, v)dv
}
.
E{dNi(tk, u)dNi(tl, v)} involves the failure time of the same subject in different
observation windows. From the definitions of Xi(tk) and Xi(tl) we can deduce that
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Pr{u ≤ Xi(tk) < u+ ∆u, δi(tk) = 1, v ≤ Xi(tl) < v + ∆v, δi(tl) = 1}
= lim
∆u→0
Pr{u ≤ Xi(tk) < u+ ∆u, δi(tk) = 1}I(v = u+ tk − tl)
= lim
∆u→0
Pr{u ≤ Xi(tk) < u+ ∆u, δi(tk) = 1|Xi(tk) ≥ u}Pr{Xi(tk) ≥ u}I(v = u+ tk − tl)
=λ(tk, u)Pr{Xi(tk) ≥ u}I(v = u+ tk − tl)du,
where du/∆u = 1 + o(du).
(a) tk ≤ tl (b) tk > tl
Figure A.1: Visual of relationship between follow-up intervals beginning at tk and tl
for two possible cases.
There are two cases we need to consider when calculating E{Yi(tk, u)dNi(tl, v)}:
tk ≤ tl and tk > tl. The first case is illustrated in Figure A.1(a). If we observe a
failure at time v = Xi(tl) for the observation window beginning at tl, the subject
can only be at risk up to time v + tl − tk in the observation window beginning at tk.
Therefore the expectation is only non-zero when u ≤ v + tl − tk. The second case is
illustrated in Figure A.1(b). The expectation is only non-zero when u ≤ v− (tk− tl).
When the failure occurs before calendar time tk, by definition Xi(tk) = 0. Therefore
the expectation is also non-zero when u = 0 and v < tk − tl. Note that if tk ≤ tl, the
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Pr{Xi(tk) ≥ u, v ≤ Xi(tl) < v + ∆v, δi(tl) = 1}
= lim
∆v→0
Pr{v ≤ Xi(tl) < v + ∆v, δi(tl) = 1}
{
I(u ≤ v + tl − tk) + I(u = 0)I(v < tk − tl)
}
=λ(tl, v)Pr{Xi(tl) ≥ v}
{





=λ(tk, u)Pr{Xi(tk) ≥ u}
{
I(v ≤ u+ tk − tl) + I(v = 0)I(u < tl − tk)
}
du.
Lastly, E{Yi(tk, u)Yi(tl, v)} = Pr{Xi(tk) ≥ u,Xi(tl) ≥ v}. Substituting these
results into equation (A.8) gives us σ2.
A.4 Standard probability calculations for σ2 in special case
We provide the details of the calculation of the closed form asymptotic variance,
σ2, in the special case where the failure time, Ti, follows an exponential distribution
with hazard λ. The censoring time, Ci, is independently sampled from a Uniform[A−
A∗, A] distribution, where A is the length of the study with accrual time A∗. The
closed form asymptotic variance for this special case is required in Section 2.5 on page
15.
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For u, v ∈ (0, τ ], we have the following result:
Pr{Xi(tk) ≥ u}
=Pr{min(Ti − tk, Ci − tk)I(Ti ≥ tk, Ci ≥ tk) ≥ u}
=E[I{min(Ti − tk, Ci − tk)I(Ti ≥ tk, Ci ≥ tk) ≥ u}]
=E[I{min(Ti − tk, Ci − tk) ≥ u}I(Ti ≥ tk)I(Ci ≥ tk)]
=E{I(Ti − tk ≥ u)I(Ci − tk ≥ u)I(Ti ≥ tk)I(Ci ≥ tk)}
=E{I(Ti − tk ≥ u)I(Ti ≥ tk)}E{I(Ci − tk ≥ u)I(Ci ≥ tk)}
=Pr(Ti ≥ u+ tk)Pr(Ci ≥ u+ tk)
=exp(−λ(u+ tk))




Pr(Xi(tk) ≥ u,Xi(tl) ≥ v)
=Pr{min(Ti − tk, Ci − tk)I(Ti ≥ tk, Ci ≥ tk) ≥ u,
min(Ti − tl, Ci − tl)I(Ti ≥ tl, Ci ≥ tl) ≥ v}
=E{I(Ti − tk ≥ u)I(Ti ≥ tk)I(Ti − tl ≥ v)I(Ti ≥ tl)}
∗E{I(Ci − tk ≥ u)I(Ci ≥ tk)I(Ci − tl ≥ v)I(Ci ≥ tl)}
=Pr(Ti ≥ max(u+ tk, v + tl))Pr(Ci ≥ max(u+ tk, v + tl))
=exp (−λ (max (u+ tk, v + tl)))
A−max(A− A∗, u+ tk, v + tl)
A∗
.
Since we assume exponential failure times, it is expected that we have constant
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Pr(u ≤ Ti − tk < u+ ∆u)Pr(Ci ≥ u+ tk)

































+ . . .
=λ.













l=1 Pr(Xi(tl) ≥ u)
=λ.
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A.5 Alternative variance estimates













































This variance estimate is based on fitting an independence working Cox proportional
hazards model with covariate Wi(tk) = 1 for i = 1, . . . , n, k = 1, . . . , b and adjusting
the covariance matrix for the association between event times within an individual
Lin & Wei (1989).
APPENDIX B
Supplementary Materials for Chapter III
B.1 Asymptotic Distribution of Overall τ-Restricted Mean
Survival
Suppose that in the dataset of combined follow-up windows we observe M events
at internal times {0 = T0 < T1 < . . . < TM < TM+1 = τ}, where times to event
from the same individual are correlated. Let Fj{dN(Tj), Y (Tj)} = dN(Tj)/Y (Tj).
For convenience, we submerge arguments of Fj and define Gm(F0, F1, . . . , Fm) =
exp(−
∑m
j=0 Fj). We can then rewrite µ̂
∗(τ) as
∑M
m=0(Tm+1−Tm)Gm(F0, F1, . . . , Fm).
We then linearize Gm(F0, F1, . . . , Fm),m = 0, . . . ,M, via a Taylor series expansion
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{ higher order terms} . (B.4)
For s = Tm,
∑m
j=0 λ
W (Tj)dTj is a non-stochastic quantity that converges to∫ s
0
λW (u)du as n → ∞. Hence, term (B.1) converges to 0 as n → ∞. And terms
(B.3) and (B.4) converge in probability to zero if
∑m





dN(u)/Y (u)− λW (u)du
}






{dN(u)/Y (u) −λW (u)du}] converges to a distribution with finite variance.







∣∣∣∣∣ p→ 0 (B.5)












]−1∣∣∣∣∣∣ p→ 0. (B.6)





{dN(u)/Y (u) −λW (u)du}] is fi-
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l=1 Pr{Xi(tl) ≥ u}
− 1∑b











dN(tk, u)− nλ(tk, u)Pr{Xi(tk) ≥ u}du
n
∑b


























dN(tk, u)− nλ(tk, u)Pr{Xi(tk) ≥ u}du
n
∑b











The left term in (B.7) is the sum of b mean zero stochastic integrals of martin-
gales, each with finite asymptotic variance
∫ s
0
λ(tk, u)Pr{Xi(tk) ≥ u}/
[∑b
l=1 Pr{
Xi(tl) ≥ u}]2 du via the martingale central limit theorem. The asymptotic covari-








l′=1 Pr{Xi(tl′) ≥ u}][
∑b




Pr{u ≤ Xi(tk) < u+ ∆u, δi(tk) = 1, v ≤ Xi(tl) < v + ∆v, δi(tl) = 1}du dv
−λ(tk, u)Pr{Xi(tk) ≥ u}λ(tl, v)Pr{Xi(tl) ≥ v}du dv
]
,
which is also finite.







dNi(u)/n gives convergence to a normal distribution with finite variance.













dN(u)/Y (u)− λW (u)du
}
converges in probability to zero as n→∞. This com-
pletes the argument that terms (B.3) and (B.4) converge in probability to zero, leaving
us with term (B.2).
Therefore
√
















{Fj − λW (Tj)dTj}
]
.
A Taylor series expansion of Fj{dN(Tj), Y (Tj)} about the expected values of dN(Tj)
and Y (Tj), used to make the non-linear Fj terms more tractable for understanding













































































{ higher order terms}. (B.12)
Term (B.8) is equal to 0 since E{dN(Tj)} = n
∑b
k=1 λ(tk,Tj)Pr{Xi(tk) ≥ Tj}dTj
and E{Y (Tj)} = n
∑b
k=1 Pr{Xi(tk) ≥ Tj} giving E{dN(Tj)}/E{Y (Tj)} = λW (Tj)dTj.
Also, after plugging in these expectations, terms (B.10) through (B.12) can be shown
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to
p→ 0 as follows.







k=1 Pr{Xi(tk) ≥ u}][dN(u)− n
∑b
k=1 λ(tk, u)Pr{Xi(tk) ≥ u}du]
n2
[∑b









dN(tk, u)− nλ(tk, u)Pr{Xi(tk) ≥ u}du
n
[∑b
l=1 Pr{Xi(tl) ≥ u}
]2 .
By the martingale central limit theorem, each of the b terms converge to a mean zero
normal process with finite variance
∫ s
0
λ(tk, u)Pr{Xi(tk) ≥ u}/
[∑b
l=1 Pr{Xi(tl) ≥ u}
]4
du.
The finite asymptotic covariance between any two of the b stochastic integrals with








l′=1 Pr{Xi(tl′) ≥ u}]2[
∑b




Pr{u ≤ Xi(tk) < u+ ∆u, δi(tk) = 1, v ≤ Xi(tl) < v + ∆v, δi(tl) = 1}du dv
−λ(tk, u)Pr{Xi(tk) ≥ u}λ(tl, v)Pr{Xi(tl) ≥ v}du dv
]
.
Hence, applying (B.5) and Slutsky’s theorem, term (B.10)
p→ 0.










l=1 λ(tl, u)Pr{Xi(tl) ≥ u}
n2
[∑b












Yi(tk, u)− Pr{Xi(tk) ≥ u}
n
] ∑b
l=1 λ(tl, u)Pr{Xi(tl) ≥ u}[∑b
l=1 Pr{Xi(tl) ≥ u}
]3 du.
By the central limit theorem, each of the b summands converge in distribution to a
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l′=1 λ(tl′ , u)Pr{Xi(tl′) ≥ u}[∑b
l′=1 Pr{Xi(tl′) ≥ u}
]3 ∑bl′=1 λ(tl′ , v)Pr{Xi(tl′) ≥ v}[∑b
l′=1 Pr{Xi(tl′) ≥ v}
]3 du dv.
Hence an application of Slutsky’s theorem and (B.5) have term (B.11)
p→ 0. Sim-
ilar arguments applied to higher order terms show that (B.12)
p→ 0, leaving us with
term (B.9). Therefore
√

















dN(u)− λW (u)Y (u)du
n
∑b
























dNi(tk, u)− λW (u)Yi(tk, u)du∑b

























dNi(tk, u)− λW (u)Yi(tk, u)du
]
/[∑b
l=1 Pr{Xi(tl) ≥ u}
]
ds. Hence, the asymptotic distribution of
√
n{µ̂∗(τ)− µ∗(τ)}
boils down to application of the central limit theorem acting on mean zero independent
and identically distributed random variables Zi{µ̂∗(τ)} =
∑b
k=1−Zik{µ̂∗(τ)}, i =
1, . . . , n. We define Z̄{µ̂∗(τ)} =
∑n
i=1 Zi{µ̂∗(τ)}/n. By the central limit theorem
√
n[Z̄{µ̂∗(τ)} − 0] has a limiting mean 0 normal distribution with finite variance
σ2∗ = V ar[Zi{µ̂∗(τ)}].




i=1 [zi{µ̂∗(τ)} − z̄{µ̂∗(τ)}]
2 /(n−
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1) where z̄{µ̂∗(τ)} =
∑n



















B.2 Asymptotic Distribution of T∗




















n2 {µ̂∗2(τ)− µ∗2(τ)} .
In Appendix B.1 we show that
√
ng{µ̂∗g(τ)−µ∗g(τ)}, g = 1, 2, each converge in dis-
tribution to a normal with mean 0 and variance σ2∗g. Slutsky’s theorem applied to the






B.3 Asymptotic Distribution of the Area under µ(t, τ) from
t1 to tb





Since µ̂(tk, τ) is a special case of µ̂
∗(τ) for b=1, results from Appendix B.1
show that
√
























Incorporating these results into the integrated τ -RMRL estimator,
√
n{µ̂(·, τ) −


































where Zi{µ̂(·, τ)} =
∫ tb
t1
−Zik{µ̂(tk, τ)}dtk is a mean zero random variable. Let
Z̄{µ̂(·, τ)} =
∑n
i=1 Zi{µ̂(·, τ)}/n. By the central limit theorem
√
n[Z̄{µ̂(·, τ)} − 0]
has a limiting mean 0 normal distribution with finite variance σ2R = V ar[Zi{µ̂(·, τ)}].




i=1 [zi{µ̂(·, τ)} − z̄{µ̂(·, τ)}]
2
/(n− 1) where z̄{µ̂(·, τ)} =
∑n




















B.4 Asymptotic Distribution of TR
















n2 {µ̂2(·, τ)− µ2(·, τ)} .
In Appendix B.3 we show that
√
ng{µ̂g(·, τ)− µg(·, τ)} each converge in distribu-
tion to a mean 0 normal with variance σR,g, g = 1, 2. By Slutsky’s theorem we have
that the expression above converges in distribution to a mean zero normal random





B.5 Spacing of Follow-up Windows
The choice of {t1, . . . , tb} should be governed by potential to make efficiency gains
in estimating µ∗(τ). To gain intuition we consider the special case where a single
event occurs for each patient. In this case, derivation of an asymptotic closed form
variance of µ̂∗(τ) is tractable and efficiency of different spacings between {t1, . . . , tb}
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l′=1 Pr{Xi(tl′) ≥ u}
] [∑b
l′=1 Pr{Xi(tl′) ≥ v}
]×
[
λ(tk, u)Pr{Xi(tk) ≥ u}I(v = u+ tk − tl)du
−λW (u)λ(tl, v)Pr{Xi(tl) ≥ v}{I(u ≤ v + tl − tk) + I(u = 0)I(v < tk − tl)}du dv
−λW (v)λ(tk, u)Pr{Xi(tk) ≥ u}{I(v ≤ u+ tk − tl) + I(v = 0)I(u < tl − tk)}du dv
+λW (u)λW (v)Pr{Xi(tk) ≥ u,Xi(tl) ≥ v}du dv
−{λ(tk, u)− λW (u)}{λ(tl, v)− λW (v)}Pr{Xi(tk) ≥ u}Pr{Xi(tl) ≥ v}du dv
]
ds ds′.
In the special case where the event time follows an exponential distribution and the
censoring mechanism is uniform, λ(tk, u) = λ
W (u) = λ. Also, standard probability
calculations for u, v ∈ (0, τ ] give Pr{Xi(tk) ≥ u} = exp{−λ(u + tk)}{A −max(A −
A∗, u+ tk)}/A∗ and Pr{Xi(tk) ≥ u,Xi(tl) ≥ v} = exp {−λmax (u+ tk, v + tl)} {A−
max(A−A∗, u+tk, v+tl)}/A∗, where A is the length of the study with accrual time, A∗.
In the results that follow we assume n = 100, an exponential hazard corresponding to
µ∗(12) = 11 months (τ = 12 months) and a uniform(24,36) administrative censoring
mechanism.
Figure B.1 evaluates the potential for an overlapping follow-up window to con-
tribute efficiency in estimation of µ̂∗(τ). Fixed (non-overlapping) follow-up windows
at t1 = 0 and t3 = 12 are included in estimation and the vertical axis shows values
of the closed form asymptotic variance as an additional follow-up window starting at
t2 ∈ (0, 12) is used in estimation. We observe that an additional 12-month window
starting at 6 months optimizes the available precision from including a single overlap-
95
ping follow-up window. Since the time-scale used in these calculations is arbitrary,
Figure B.1 suggests that a window evenly spaced between two existing windows has
the best potential to improve efficiency.
Figure B.1: Finite sample (n = 100) closed form asymptotic variance of µ̂∗(τ) as-
suming a single exponential event time for a 36 month study with an
administrative censoring mechanism when τ=12 months. t1 = 0, t3 = 12
months and we vary t2. Dashed line corresponds to variance of estimator
constructed using two follow-up windows t1 = 0 and t3 = 12.
Table B.1 explores the potential for efficiency gain with additional equally spaced
follow-up windows. The optimal variance identified in Figure B.1 is shown for the
case with tb = 12 with 3 windows; the dashed line in this figure corresponds to tb = 12
with 2 windows. Asymptotic relative efficiencies relative to use of a single window
at tb = 0 are given in the final column. Results indicate (a) additional follow-up
time, as indicated by increasing tb, provides the highest improvement in efficiency
and (b) introducing windows more frequently that at 6-month intervals results in
diminishing returns. Gains provided by (a) may require additional resources in the
implementation of a clinical trial, whereas available gains provided by (b) are cost-free.
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Based on this special case, we recommend using intervals starting from tk = (k−1)τ/2
for k = 1, . . . , b, where b is chosen so that the final follow-up interval starting at tb
does not exceed the study period. Simulation methods are recommended to explore
the merits of more complex designs than given here.
Table B.1: Study of follow-up window choices based on finite sample (n = 100) closed
form variance (σ2/n) and Asymptotic Relative Efficiency (ARE) for the
special case were we assume a single exponential event time per patient
in a 36 month study with an administrative censoring mechanism.
Number of {t1, . . . , tb} σ2/n ARE
Windows
tb = 0 1 0 0.071 1.00
tb = 12
2 0, 12 0.039 1.82
3 0, 6, 12 0.035 2.03
5 0, 3, 6, 9, 12 0.035 2.03
tb = 24
3 0, 12, 24 0.030 2.37
5 0, 6, 12, 18, 24 0.026 2.73
9 0, 3, 6, 9, 12, 15, 18, 21, 24 0.025 2.84
B.6 Simulation Study: Empirical Mean 12-month RMRL
The plot of the empirical mean 12-month RMRL for group 1 and for each value
of alpha for group 2 is given in Figure B.2, B.3 and B.4 for scenarios of immedi-
ate treatment effect, delayed treatment effect and short duration treatment effect
respectively.
In these plots we observe that assuming proportional hazard results in constant
parallel trajectories for the τ -RMRL when the events are uncorrelated. When the
events are correlated, we no longer have constant τ -RMRL functions, but rather the
τ -RMRL are initially decreasing then constant. We were initially perplexed by why
this would be the case. In order to better understand the dependent data structure
we considered the simpler scenario where we only have recurrent events with no
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(b) Strongly correlated events
Figure B.2: Plot of the empirical mean 12-month RMRL for group 1 (black) and for
each value of alpha for group 2 (α = 1: red, α = 0.9: green, α = 0.8: dark
blue, α = 0.7: light blue, α = 0.6: pink) when we assume proportional
hazards.
terminating events. In this case the simulations still showed decreasing τ -RMRL
functions with greater slopes for stronger positive correlations. To explain the τ -
RMRL function at 6 months, we need to understand the distribution of the next
event from 6 months. T1 and T2 are the times to recurrent event from time 0. They
are defined as T1 = S1 and T2 = S1 + S2 in terms of gap times S1 and S2. In our
simulations, we assume gap times are exponentially distributed with parameter λS.
If T1 > 6 then the next event at 6 months will follow the same exponential
distribution as time 0, i.e ∼ Exponential(λS). If T1 < 6 and T2 > 6 then the next
event from 6 months ∼ T2|T1 < 6, T2 > 6. The survival function of this distribution is
Pr(T2 > t, T1 < 6)/Pr(T2 > 6, T1 < 6) for t > 6. The probability Pr(T2 > t, T1 < 6)
98





















































(b) Strongly correlated events
Figure B.3: Plot of the empirical 12-month RMRL for group 1 (black) and for each
value of alpha for group 2 (α = 1: red, α = 0.9: green, α = 0.8: dark blue,
α = 0.7: light blue, α = 0.6: pink) when we assume delayed proportional
treatment effect.
can be written in terms of the random variables S1 and S2,
Pr(T2 > t, T1 < 6)




Pr(S2 > t− s|S1 = s)fS1(s)ds.
If S1 and S2 are independent, the survival function of T2|T1 < 6, T2 > 6 is
exp{−λS(t− 6)} for t > 6, i.e ∼ Exponential(λS). If S1 and S2 are positively corre-
lated Pr(S2 > t − s|S1 = s) < Pr(S2 > t − s), where s ∈ [0, 6) and t > 6, since S1
is small and therefore S2 is then more likely to be small. We can define k(t) to be a
function such that
Pr(T2 > t, T1 < 6)
=k(t)6λS exp(−λSt),
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(b) Strongly correlated events
Figure B.4: Plot of the empirical 12-month RMRL for group 1 (black) and for each
value of alpha for group 2 (α = 1: red, α = 0.9: green, α = 0.8: dark
blue, α = 0.7: light blue, α = 0.6: pink) when we assume short duration
treatment effect.
where 0 < k(t) < 1 for t > 6 and is a decreasing function of t. Intuitively k(t) must be
a decreasing function because when S1 and S2 are positively correlated the conditions
on S2 are more restrictive and it is less likely that S2 > t − s for any s ∈ [0, 6).
Therefore the survival function of T2|T1 < 6, T2 > 6 is k(t) exp{−λS(t − 6)}/k(6)
where k(t)/k(6) < 1 for t > 6. Therefore the area under the survival function up to
τ is smaller for positively correlated recurrent events.
APPENDIX C
Supplementary Materials for Chapter IV
C.1 Patient specific hazards
To simulate the failure time Ti for i = 1, . . . , n, we require patient specific hazards




v ≤ 6) + λi2I(6 < v ≤ 12) + λi3I(12 < v < ∞)]dv}, that obey the restricted mean
model E(log[min{Ti(tj), τ}]) = β0 + β1Z1i(tj) + β2Z2i.
Therefore we have




log(u)dP{Ti − tj > u|Ti > tj, Z̄1(u+ tj), Z2}
+ log(τ)P{Ti − tj > τ |Ti > tj, Z̄1(τ + tj), Z2},
for each window tj, j = 1, 2, 3. In this case we have three nonlinear equations with
three unknown parameters that we need to solve for: λi1, λi2 and λi3. In each case
the solution is obtained using numerical algorithms for nonlinear equations.
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Starting with j = 3, we have




log(u)λi3 exp{−uλi3}du+ log(12) exp{−12λi3},
where λi3 is the only unknown quantity.
For j = 2, we have







log(u)λi3 exp{−6λi2 − uλi3}
+ log(12) exp{−6λi2 − 6λi3},
where λi2 is the only unknown quantity.
For j = 1, we have








log(u)λi2 exp{−6λi1 − uλi2}+ log(12) exp{−6λi1 − 6λi2},
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